

Vaccines and Global Health: The Week in Review 23 August :: Issue 811 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

Vaccines and Global Health: The Week in Review resumes publication with this issue following the Editor's annual leave.

Milestones, Perspectives

WHO - Strategic Advisory Group of Experts on Immunization (SAGE) - September 2025 22 - 25 September 2025

This meeting for the Strategic Advisory Group of Experts on Immunization (SAGE) will be held from Monday to Thursday

:: Draft Agenda

:::::::

::::::::

WHO designates new WHO-Listed Authorities, strengthening global access to qualityassured medical products

7 August 2025 News release

The World Health Organization (WHO) has officially designated **Health Canada**, the **Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan**, and the **Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom** as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products.

With these latest designations, WHO expands the growing list of WLAs, now involving 39 agencies across the world, supporting faster and broader access to quality-assured medical products, particularly in low- and middle-income countries (LMICs).

In addition, the Republic of Korea's Ministry of Food and Drug Safety (MFDS) – one of the first regulatory authorities to complete the WLA assessment for both medicines and vaccines in October 2023 – has had its listing scope successfully expanded, now covering all regulatory functions.

"This recognition reflects the deep commitment of these authorities to regulatory excellence," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Their designation as WHO-Listed Authorities is not only a testament to their robust regulatory systems but also a critical contribution to global public health. Strong and trusted regulators help ensure that people everywhere have access to safe, effective, and high-quality medical products."...

The designations follow a rigorous performance evaluation process carried out by WHO using its globally recognized benchmarking and assessment tools. These evaluations were reviewed by the Technical Advisory Group on WLAs (TAG-WLA), which convened in June 2025.

Canada, Japan and the UK's regulatory authorities were previously recognized as Stringent Regulatory Authorities (SRAs). Their designation under the WLA framework marks an important step in moving beyond the old SRA system, while ensuring continuity and stability in global procurement processes of quality-assured medical products.

Launched in 2022 to replace the previous SRA model, the WLA initiative provides a transparent and evidence-based pathway for global recognition of regulatory authorities to facilitate regulatory convergence and reliance. It builds on decades of WHO leadership to help countries work together more closely on regulating medical products, speeding up access to safe, effective and quality-assured medical products for people around the world.

:::::::

<u>Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered</u> Research and Innovation

Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally

SEATTLE (August 4, 2025) – **The Gates Foundation today announced a \$2.5 billion commitment** through 2030 to accelerate research and development (R&D) focused exclusively on women's health.

It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries.

The foundation's investment will advance innovation across five high-impact areas of a woman's lifespan:

- :: Obstetric care and maternal immunization: Making pregnancy and delivery safer
- :: Maternal health and nutrition: Supporting healthier pregnancies and newborns
- **:: Gynecological and menstrual health:** Advancing tools and research to better diagnose, treat, and improve gynecological health and reduce infection risk
- **:: Contraceptive innovation**: Offering more accessible, acceptable, and effective options
- **:: Sexually transmitted infections (STIs):** Improving diagnosis and treatment to reduce disproportionate burdens on women

...The five priority areas were selected based on a combination of data and evidence about where innovation can save and improve the most lives, direct insights from women in low- and middle-income countries about their needs and preferences, and the persistently high rates of misdiagnosis caused by gaps in medical knowledge and training. They also reflect the unique challenges faced in low-resource settings, making these areas especially ripe for broader public and private investment to drive meaningful, scalable impact...

.....

Polio - PHEIC

Polio this week [20 August 2025]

Headlines [Selected]

- :: "Eradicating polio part of our journey of independence." Senator Ayesha Raza, Pakistan Prime Minister's Focal Person on Polio Eradication. Click <u>here</u> for an inspiring video message celebrating Pakistan's Independence Day.
- :: This week, the Polio Working Group of the Strategic Advisory Group of Experts on immunization (SAGE) is meeting at WHO in Geneva, Switzerland. The group is expected to review the latest global epidemiology, impact of various strategic and tactical approaches, and discuss potential additional programmatic innovations such as expanded use of novel oral polio vaccine type 2 (nOPV2). Outcomes of the deliberations will be presented to the full SAGE meeting, on 22-25 September.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: two WPV1 cases and 42 WPV1-positive environmental samples
- Angola: one cVDPV2 case
- Central African Republic: one cVDPV2 case

DR Congo: one cVDPV1 case

- Tanzania: one cVDPV2-positive environmental sample

Yemen: 26 cVDPV2 cases

:::::::

WHO Disease Outbreak News

20 August 2025 | Circulating vaccine-derived poliovirus type 1 - Israel

Situation at a glance

On 4 August 2025, Israel notified WHO of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak. Between February and July 2025, nine genetically linked virus isolates were found in environmental samples from seven sites, mainly in Jerusalem and the Central Region. No human cases of paralytic polio have been reported. Israel discontinued routine use of the bivalent oral polio vaccine in March 2025 but continues using inactivated polio vaccine (IPV) as part of the country's routine immunization schedule. WHO and partners of the Global Polio Eradication Initiative are supporting national and subnational authorities. WHO assesses the risk of international spread of this cVDPV1 outbreak in Israel as low, due to strong overall immunity, surveillance, and response systems. However, the virus is circulating in under-vaccinated, vaccine-sceptic communities with ties to similar groups abroad, posing a potential risk for further spread.

::::::::

<u>Update from the Global Polio Eradication Initiative on programmatic challenges and accountability</u>

07/08/2025

The final phase of the polio eradication effort has proven to be the toughest. The number of children paralyzed by polio has been reduced by 99% over the last four decades, but the virus continues to spread in some of the most difficult places on the planet to deliver healthcare— places that face persistent insecurity, political instability and weak health infrastructure. This context limits families' access to formal health services and hinders health workers' tireless efforts to reach every child with life-saving vaccines, including for polio.

To drive progress toward eradication in these settings, the polio program works to support national and local teams to develop tailored solutions and make ongoing adjustments to better meet community needs. In some places, the program co-designs operational improvements with frontline health workers, which has led to expanded trainings, enhanced safety measures and improved outbreak response protocols.

At the same time, the program regularly consults expert groups on its strategic decisions, including the <u>Independent Monitoring Board</u> (IMB), the <u>Strategic Advisory Group of Experts on Immunization</u> (SAGE), and the <u>Emergency Committee under the International Health Regulations</u> (IHR). Ultimately, we answer to countries around the world through the <u>World Health Assembly</u>. Few other global health programs incorporate this level of independent evaluation into their structure...

...The GPEI remains committed to transparency, to learning from setbacks, and to working with all partners—including scientific experts, frontline health workers, donors, policymakers and affected communities—to finish the job and deliver a polio-free world for children today and generations to come.

::::::::

mPox - PHEIC

No new digest content identified.

:::::::

Featured Journal Content

Annals of Internal Medicine

August 2025 Volume 178, Issue 8

https://www.acpjournals.org/toc/aim/current

Ideas and Opinions

<u>Preserving Scientific Integrity in Vaccine Policy: The Role of, and Risk to, the CDC's Advisory Committee on Immunization Practices</u>

Jason M. Goldman, MD and Sandra Adamson Fryhofer, MD

Pages:1197-1198

In 1964, the U.S. Secretary of Health and Human Services established the Advisory Committee on Immunization Practices (ACIP) as a trusted, transparent, and evidence-based public body charged with making vaccine recommendations. Operating under the Centers for Disease Control and Prevention (CDC), ACIP has played a vital role in ensuring the safety, effectiveness, and appropriate use of vaccines. Its recommendations influence public health policy, clinical practice, insurance coverage, and ultimately the lives of millions of Americans (1). Until recently, the ACIP was not merely a bureaucratic body—it was a cornerstone of national health policy. It deserves our protection and our voice.

The ACIP has been a model of rigorous scientific and democratic public health decision making. It was designed to engender public confidence in vaccines through open deliberation, multidisciplinary expertise, and thorough vetting of conflicts of interest. For clinicians and the public, it has served as a reliable source of information and guidance.

However, a troubling shift has emerged—one that threatens to undermine ACIP's structure. The increasing politically motivated changes to its membership raise serious concerns about the integrity of its recommendations. These developments endanger public trust in vaccines, the authority of medical science, patient safety, and the health of the public (2-4).

There have always been vaccine skeptics, but mistrust has reached new levels in the post–COVID-19 landscape (5). This distrust makes ACIP's role more essential than ever. The committee has historically functioned through the diligent work of subject matter experts who are rigorously vetted for conflicts of interest. Their appointments follow a transparent process, and any existing conflicts are publicly disclosed. Members with conflicts are recused from voting on relevant matters to preserve impartiality and public confidence.

Beyond the voting committee members, ACIP has also relied heavily on a network of liaison representatives. These representatives of medical societies, professional organizations, and public health groups contribute frontline perspectives via their direct work with patients, families, and communities. Although the liaisons do not vote, they provide essential context and real-world insights that shape ACIP discussions and the eventual recommendations.

Collectively, we have served as liaisons to ACIP for nearly 2 decades, participating in multiple work groups, helping to analyze data, and evaluating evidence to inform the committee's decisions. We have seen firsthand how essential the collaborative process is. The committee's work is not simply a matter of showing up and voting. It involves months and sometimes years of preparation, scientific review, stakeholder engagement, and deliberation. Work groups, made up of CDC staff, committee members, and liaisons, often meet weekly to examine new data, evaluate study quality, assess the benefits and risks of proposed interventions, and consider the feasibility of implementation.

The level of detail and diligence of this process cannot be replicated by someone stepping into the process at the last minute. The recent removal and replacement of committee members for what appears to be political reasons is deeply concerning. Such actions compromise the integrity of the process, the scientific integrity of the recommendations, and the public's trust.

The ACIP's credibility rests on its independence and the expertise of its members. It was built to safeguard against political interference and to incorporate diverse perspectives concerning clinical, epidemiologic, economic, and social concerns. The result was evidence-based recommendations. Weakening these pillars risks collapse of the entire structure.

Liaisons and committee members, far from being rubber stamps, are often the most vocal critics of data presented by manufacturers. They have pushed for transparency, demand better-quality evidence, and advocate for patient-centered implementation strategies. Liaison organizations, including the American College of Physicians, American Medical Association, American Academy of Pediatrics, and many others, represent clinicians and advocates who care directly for patients, seek better health outcomes, and see the consequences of vaccine decisions. We know what happens when public trust erodes, misinformation spreads, and policy is divorced from science.

The ACIP has also been a model of public accountability. Meetings have been open to the public, recorded, and archived. Comment periods are built into the process, allowing patients, advocates, and concerned citizens to weigh in. The committee has not operated behind closed doors; rather, it is a public forum grounded in scientific rigor and community engagement.

It is therefore inconceivable that political actors would seek to shortcut this process by marginalizing experienced members or installing replacements with insufficient preparation. The technical and scientific complexity of vaccine evaluation demands expertise, preparation, and a commitment to objectivity. One cannot reasonably expect informed, meaningful contributions from someone brought into the process just days before a vote.

The stakes are far too high. Vaccines are among the most effective tools in our public health arsenal. They have eradicated diseases, prevented outbreaks, reduced morbidity and mortality rates, and saved countless lives. Their success depends not only on biological efficacy but also on public trust. When decisions about vaccines are perceived as politically motivated rather than scientifically grounded, trust is the first casualty $(\underline{5}, \underline{6})$.

The damage is not hypothetical. It is already visible. Vaccine uptake for routine immunizations has declined in some regions $(\underline{2}, \underline{7})$. Confidence in public health recommendations has been shaken. Misinformation spreads more rapidly than ever $(\underline{4})$. The way to address these challenges is not to undermine the scientific process, but to protect and strengthen it.

Medical and public health professionals must reaffirm our commitment to a vaccine policy grounded in evidence, transparency, and public health principles. This means demanding the preservation of ACIP's independence, valuing the voices of experienced liaisons, resisting political interference, and reinforcing the role of the CDC as a scientific, not a political, institution. The process is not perfect, but it is built on integrity, inclusivity, and decades of collective expertise. Allowing ACIP to be diluted, politicized, or manipulated puts lives at risk. We owe it to our patients, our colleagues, and our communities to speak up.

......

EMBO Reports

Volume 26 Issue 16 22 August 2025

https://www.embopress.org/toc/14693178/current

Science & Society 31 July 2025

<u>Fool's-gold science: The ethical and scientific perils of testing most vaccines using</u> placebo-controlled randomized trials

Arthur Caplan, Felicia L Pasadyn, Nathaniel Mamo

The US Department of Health and Human Services' proposed imposition of placebo-controlled trials for testing most new and existing vaccines jeopardizes public health and puts trial participants at unnecessary and easily avoidable risks—a violation of both scientific and ethical standards. ...Conclusion

Calls or policies requiring the use of placebos to test vaccines are ethically flawed and unsound in their insistence that this is the only method for generating credible or so-called 'gold standard' science. The American Academy of Pediatrics has already stated that it will not follow these demands, rather issuing their own evidence-based guidelines. Essentially, Secretary Kennedy Jr. and HHS are asking the American public to start from scratch again, testing vaccines that have already been proven safe and effective. Far from upholding scientific rigor, such demands distort the purpose of trials and jeopardize public health (Gostin and Reiss, 2025). They hasten the erosion of herd immunity, already under strain for diseases such as measles due to declining vaccination rates. Rebuilding public confidence and restoring coverage will take years, if not decades. No sponsor, investigator, research ethics committee, manufacturer, or regulator ought to participate in trials that disregard existing evidence and indefensibly expose populations to preventable harm under the false guise of scientific purity. Demanding such trials for proven interventions is not only scientifically unsound but also ethically indefensible.

::::::::

Globalizing Vaccines: A Post-COVID Perspective on Industrial Policy, International Health Cooperation, and the Characteristics of Vaccine Production

Center for Global Development – *CGD Note* William D. Savedoff August 13, 2025 *Preface*

The COVID-19 pandemic exposed both the extraordinary potential and persistent limitations of global health cooperation. While the world witnessed the rapid development of safe and effective vaccines, the promise of global solidarity quickly gave way to a harsh realpolitik: wealthy nations prioritized vaccines for their own populations, leading to delayed, insufficient, and inequitable distribution in many low- and middle-income countries, most notably in Africa.

This CGD Note explores this challenge and its implications for future policies related to vaccine production and pandemic preparedness more broadly. Drawing on firsthand insights and research on industrial and political trends, the note examines how countries can diversify vaccine production in a world shaped by globalized supply chains and strategic dependencies.

Specifically, it examines long-term economic and political shifts that have shaped current trends in vaccine production. These include:

- (1) the global retreat from industrial policy;
- (2) the erosion of international health cooperation; and
- (3) the complex technological and regulatory realities of vaccine development and manufacturing.

The conclusion explores alternative scenarios for geographically diversifying vaccine production, providing valuable insights to guide current and future efforts in building more resilient regional vaccine manufacturing ecosystems.

[Excerpt]

...Looking forward, each country is going to have to make choices about how best to assure the vaccines it needs considering the prices it is willing to pay and the risks it is willing to assume.

The existence of regional or global agreements expands the available options but if they are not forthcoming, then the range of policies available to countries might look like this:

- Accept dependence in return for low-cost vaccines and seek other ways to mitigate
 potential fallout from crises that interrupt supply, such as stockpiling, purchasing insurance, or
 negotiating contracts with major manufacturers based on a retainer fee model.
- **Engage with major vaccine-producing centers** and develop elements of the vaccine production process that are separable, such as fill and finish or clinical testing, to leverage preferential access to vaccines when needed.
- Reject dependence on external firms and countries and invest in domestic
 production despite the costs. This requires an assessment of the scale of investments and
 actions required and setting priorities for which vaccines can and will be domestically produced.
 This is a costly and difficult strategy, but it is not impossible (see Box 2).
- Plan for dependence but work to build regional or global agreements that support new innovation hubs with strong political agreements that ensure sharing technology, distributing production, and assuring equitable provision.

Currently, regional and global initiatives aimed at promoting geographical diversification are quite active. For example, PAHO is seeking to build capacity for mRNA vaccine technologies in Latin America. The European Union and others are supporting African initiatives to build the continent's capacity to produce 60 percent of its vaccine demand. The Coalition for Local and Regional Production, Innovation and Equitable Access was launched at a G-20 meeting in Rio de Janeiro as a form of voluntary cooperation to promote access to vaccines and related health technologies. ASEAN has its Vaccine Security and Self-Reliance Strategic and Action Plan (2021–25) aimed at increasing the region's access to vaccines by prioritizing areas of cooperation and supporting manufacturing hubs.

Geographical diversification of vaccine manufacturing as envisioned by these initiatives is possible, but it is not easy. Long-term trends in the globalization of manufacturing and international cooperation on health, combined with the high costs of building a vaccine manufacturing infrastructure, encourage concentration of production in relatively few centers.

Without substantial political effort to create cross-national binding agreements, finance and establish credible commitments to purchase vaccines in the future, and build local capacity to provide stringent regulation of safety and efficacy, the tendency to concentrate vaccine production is likely to continue unchecked.

••••	•••
:::::	

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: <u>U.S. Immunization and Public Health Governance/Policy/Funding</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

:: Think Tanks

:: Public Consultations/Call for Inputs/Call for Papers

::::::::

WHO & Regional Offices [to 02 Aug 2025]

https://www.who.int/news

Selected News/Announcements/Statements

22 August 2025 Joint News Release

Famine confirmed for first time in Gaza

FAO, UNICEF, WFP and WHO reiterate call for immediate ceasefire and unhindered humanitarian access to curb deaths from hunger and malnutrition

22 August 2025 Joint News Release

More than half a million people in Gaza are trapped in famine, marked by widespread starvation, destitution and preventable deaths, according to a new <u>Integrated Food Security Phase Classification</u> (<u>IPC</u>) analysis released today. Famine conditions are projected to spread from Gaza Governorate to Deir Al Balah and Khan Younis Governorates in the coming weeks...

22 August 2025 Joint News Release

WHO, WMO issue new report and guidance to protect workers from increasing heat stress

19 August 2025 Departmental update

Executive Board approves revised WHO Evaluation Policy (2025)

June 2025: At its 157th session, the Executive Board of the World Health Organization (WHO) approved the revised Organization-wide Evaluation Policy (2025), updating the earlier 2018 version, aimed at strengthening accountability, transparency, organizational learning, evidence-based decision-making and performance across the Organization. The Policy reinforces evaluation as the cornerstone of results-based management. The Policy reflects key evolutions in the professional practice of evaluation and the structure and operations of evaluation functions across the UN.

15 August 2025 Departmental update

Steering Committee established for second WHO Global Summit on Traditional Medicine

14 August 2025 Departmental update

World Patient Day 2025: explore free courses to enhance newborn and child health

13 August 2025 Departmental update

WHO recommends spatial emanators for malaria vector control and prequalifies first two products

13 August 2025 Departmental update

WHO releases new Target Product Profiles for tuberculosis screening tests

12 August 2025 Departmental update

WHO launches Health Inequality Monitoring Network to catalyse progress towards health equity

11 August 2025 Departmental update

Outcomes of the Fifth Global Conference on Climate and Health

11 August 2025 Departmental update

WHO releases an update to the operational handbook on diagnosis of tuberculosis

8 August 2025 Departmental update

WHO calls for parliamentary leadership on health at the Sixth World Conference of Speakers of Parliament

8 August 2025 News release

Kenya achieves elimination of human African trypanosomiasis or sleeping sickness as a public health problem

7 August 2025 News release

WHO designates new WHO-Listed Authorities, strengthening global access to qualityassured medical products

The World Health Organization (WHO) has officially designated Health Canada, the Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, and the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products.

With these latest designations, WHO expands the growing list of WLAs, now involving 39 agencies across the world, supporting faster and broader access to quality-assured medical products, particularly in low- and middle-income countries (LMICs).

In addition, the Republic of Korea's Ministry of Food and Drug Safety (MFDS) – one of the first regulatory authorities to complete the WLA assessment for both medicines and vaccines in October 2023 – has had its listing scope successfully expanded, now covering all regulatory functions.

"This recognition reflects the deep commitment of these authorities to regulatory excellence," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Their designation as WHO-Listed Authorities is not only a testament to their robust regulatory systems but also a critical contribution to global public health. Strong and trusted regulators help ensure that people everywhere have access to safe, effective, and high-quality medical products."...

7 August 2025 Departmental update

WHO and partners launch global guide to advance respectful maternal and newborn care

6 August 2025 Departmental update

<u>Climate change and global health: WHO calls for migrant-inclusive and climate-resilient health systems</u>

6 August 2025 Departmental update

WHO releases new target product profile for diagnostic tests to detect serious bacterial infections in young infants

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 20 August 2025

Cholera Response in Congo: Mbamou Island Breathes Again

:: 18 August 2025

Rapid response halts diphtheria outbreak among refugees in Mauritania

:: 14 August 2025

Sustaining efforts to end mpox outbreaks in Africa

WHO Region of the Americas PAHO

:: 22 Aug 2025

<u>Latin American and Caribbean laboratories strengthen zoonotic influenza detection</u> <u>through joint PAHO-IAEA workshop</u>

Rio de Janeiro, August 22, 2025 (PANAFTOSA/SPV-PAHO/WHO) – Laboratory technicians from 19 Latin American and Caribbean countries completed a five-day workshop in Rio de Janeiro to enhance the detection of avian influenza A (H5N1), a virus responsible for over 4,700 reported outbreaks in birds and mammals and more than 70 human cases in the...

:: 22 Aug 2025

<u>Countries of the Americas advance toward regional strategy to tackle the health threat from venomous animal accidents</u>

São Paulo, Brazil, 21 August 2025 (PAHO) – Countries across Latin America and the Caribbean have advanced toward a regional strategy to address the growing health burden of accidents caused by venomous animals. From snakebites and scorpion stings to encounters with venomous spiders and caterpillars, these incidents claim hundreds of lives annually...

:: 21 Aug 2025

PAHO convenes experts to strengthen Oropouche surveillance in the Region

São Paulo, Brazil, August 21, 2025 – The Pan American Health Organization (PAHO) convened in São Paulo regional experts in surveillance, virology, clinical practice, genetics, and congenital malformations from Argentina, Brazil, Chile, Uruguay, Cuba, Costa Rica, and Nicaragua, together with technical teams from BIREME, the PAHO Country Office in...

:: 15 Aug 2025

Ten countries in the Americas report measles outbreaks in 2025

PAHO calls for action to close immunization gaps Washington, D.C., 15 August 2025 (PAHO) – The Pan American Health Organization (PAHO) is urging countries in the Americas to strengthen immunization activities, enhance disease surveillance and rapid response interventions, as measles cases continue to rise in the region. As of 8 August 2025, a total...

:: 14 Aug 2025

PAHO publishes new update on Oropouche fever in the Americas

Washington, D.C., August 14, 2025 (PAHO) – The Pan American Health Organization (PAHO) has issued a new epidemiological update on Oropouche fever, a viral disease that has resurged across the Americas since late 2023. So far in 2025, 12,786 confirmed cases have been reported across 11 countries — seven with local transmission and four with...

:: 7 Aug 2025

WHO designates new WHO-Listed Authorities, strengthening global access to qualityassured medical products

Geneva, 07 August 2025 (WHO) –The World Health Organization (WHO) has officially designated Health Canada, the Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, and the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom as WHO-Listed Authorities (WLAs), a status

WHO South-East Asia Region SEARO

:: 18 August 2025 News release
Nepal eliminates rubella

WHO European Region EURO

No new digest content identified.

WHO Eastern Mediterranean Region EMRO

:: Famine confirmed for first time in Gaza

FAO, UNICEF, WFP and WHO reiterate call for immediate ceasefire and unhindered humanitarian access to curb deaths from hunger and malnutrition

WHO Western Pacific Region

No new digest content identified.

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

15 August 2025

Public Health Situation Analysis - Syrian Arab Republic

Syrians are enduring one of the world's most complex emergencies, a combination of protracted hostilities, repeated displacement of civilians, economic recession, disease outbreaks, and devastating earthquake...

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

20 August 2025 | Circulating vaccine-derived poliovirus type 1 - Israel

:::::::

Weekly Epidemiological Record

Vol. 100, Nos. 32/33, pp. 309–320 8 August 2025 https://www.who.int/publications/journals/weekly-epidemiological-record :: A dual battle: rabies and snakebite envenoming in South-East Asia

::::::

New WHO Publications

https://www.who.int/publications

Selected

19 August 2025

Report of the 48th meeting of the WHO Global Advisory Committee on Vaccine Safety, 15–16 May 2025

19 August 2025

Optimal and early inclusion of pregnant and lactating women in tuberculosis research: consensus statement

19 August 2025

Accelerating research to end tuberculosis in pregnant and lactating women: a call to action

...This consensus statement summarizes the consensus process, which included five thematic working groups (covering preclinical TB research, TB therapeutics research, TB vaccine research, maternal TB surveillance systems and advocacy), evidence reviews to address gaps in data and knowledge and a consensus meeting in February 2025. The approaches to earlier and optimal inclusion arising from the consensus process include crosscutting actions as well as approaches specific to each working group theme.

An accompanying <u>call to action</u> specifies actions needed to ensure full implementation of the consensus statement...

18 August 2025

<u>Tenth Meeting of the WHO South-East Asia Regional Verification Commission for Measles and Rubella Elimination</u>

18 August 2025

<u>Seventeenth Biregional Meeting of National Influenza Centres and Influenza Surveillance in WHO's South-East...</u>

15 August 2025

Behavioural and social drivers of influenza vaccination: tools and practical guidance for achieving high uptake

13 August 2025

WHO guidelines for malaria

13 August 2025

The art and science of promoting evidence-informed decision-making: a global living evidence map

Overview

Effective policy design and implementation are central to socioeconomic development and reduction of inequities. The systematic use of data and evidence to guide decision-making for policy and practice is a major pathway to arriving at more effective policies, programmes, and practices. The present evidence map aimed to assess the existing evidence on interventions that support decision-makers' use of evidence to examine the size and nature of the existing evidence base in the area. Despite the large number of studies found, a number of gaps and inequities in the evidence base were identified. These included the dominance of evidence from the health sector and high-income countries, as well as five countries that on their own contributed 41% of the total identified evidence base.

The developed evidence map and its included studies present a resource for policy-makers, researchers, and practitioners to identify research and practice gaps. It can be used to inform research commissioning, with the commissioning of more evidence synthesis on EIDM interventions being regarded as the most pressing evidence gap. The map also shines a spotlight on the absence of a shared conceptual framework, taxonomy of interventions and outcomes, and an agreed set of key indicators and outcome measures of evidence use. This presents a further fertile area for EIDM research.

13 August 2025

<u>Pandemic influenza severity assessment (PISA): a WHO guide to assess the severity of influenza in seasonal epidemics and pandemics, second edition</u>

The updated WHO pandemic influenza severity assessment (PISA) framework set out in this document provides a systematic approach for interpreting data collected through existing surveillance systems and improving their usefulness for risk communication and decision-making.

10 August 2025

<u>Second general meeting of the WHO Global Coordination Mechanism on the Prevention</u> and Control of Noncommunicable...

10 August 2025

Malaria control in emergencies: field manual

8 August 2025

<u>Target product profile on in vitro diagnostic assays for the detection of yellow fever in the context...</u>

7 August 2025

Defining access to countermeasures: landscape report 2024

Overview

This landscape report on the current status of activities related to medical countermeasures (MCMs) for pandemic response underscores the urgent need for action in this critical area. From bolstering research and development to diversifying manufacturing capacities, coordinating global procurement efforts, ensuring equitable allocation approaches for these lifesaving interventions, and making sure arrangements are in place so that they reach the very last mile and enable appropriate use by those in need, the journey toward pandemic preparedness traverses a multifaceted landscape.

Yet, despite the progress made, critical gaps in MCM-related aspects remain, and vulnerabilities urgently need to be addressed. This report explores scientific advancements and ongoing or planned activities in the field of MCMs. While there is much progress to note and acknowledge, it is evident that significant work remains to strengthen our abilities to prepare for and respond to pandemics.

Moreover, no single entity can tackle this monumental task alone. A network of networks is needed, wherein collaboration and coordination among regional and global health actors are strengthened, ensuring a coherent, streamlined, and accountable approach to pandemic preparedness. This report emphasizes the importance of collective effort in navigating the complex landscape of medical countermeasures and enhancing global health security.

7 August 2025

Target product profiles for tuberculosis screening tests

6 August 2025

Eradicating cervical cancer in Thailand: A journey of hope and progress

5 August 2025

<u>Towards a malaria-free world: elimination of malaria and prevention of re-establishment in Tajikistan</u>

5 August 2025

WHO operational handbook on tuberculosis: module 3: diagnosis

5 August 2025

Emerging from the Unknowing: WHO India's strategic response to the pandemic

4 August 2025

Report of the sixth, seventh and eighth meetings of the Technical Advisory Group on Malaria Elimination...

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we are establishing a separate section of the digest to capture and organize key content. We will selectively include and indent comment and responses to some of the actions below.

::::::::

White House, HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders; Memoranda; Proclamations

Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve

Presidential Actions, Executive Orders

August 13, 2025

Fact Sheet: President Donald J. Trump Ensures American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve Fact Sheets

August 13, 2025

... The Executive Order directs the Office of the Assistant Secretary for Preparedness and Response (ASPR), within the Department of Health and Human Services, to develop a list of approximately 26 critical drugs vital to national health and security, and ready the SAPIR repository to receive and maintain the Active Pharmaceutical Ingredients (APIs) used to make these critical drugs...

HHS

News

HHS Revives Task Force on Safer Childhood Vaccines

August 14, 2025 Press Release

WASHINGTON — The U.S. Department of Health and Human Services (HHS) today announced the reinstatement of the Task Force on Safer Childhood Vaccines, a federal panel created by Congress to improve the safety, quality, and oversight of vaccines administered to American children.

"By reinstating this Task Force, we are reaffirming our commitment to rigorous science, continuous improvement, and the trust of American families," said National Institutes of Health (NIH) Director Jay Bhattacharya. "NIH is proud to lead this effort to advance vaccine safety and support innovation that protects children without compromise."

The original Task Force was disbanded in 1998, and today's action reaffirms the Department's commitment towards continuous improvement in childhood vaccine safety oversight. The Task Force is represented by senior leadership from NIH, the Food and Drug Administration, and the Centers for Disease Control and Prevention. The NIH Director will serve as Chairman of the Task Force.

The Task Force will work closely with the Advisory Commission on Childhood Vaccines to produce regular recommendations focused on:

- The development, promotion, and refinement of childhood vaccines that result in fewer and less serious adverse reactions than those vaccines currently on the market.
- Improvements in vaccine development, production, distribution, and adverse reaction reporting along with supporting research to make vaccines safer.

HHS will transmit its first formal report to Congress within two years, with updates every two years thereafter.

HHS Winds Down mRNA Vaccine Development Under BARDA

August 5, 2025 Press Release

WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) today announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA), including the cancellation and descoping of various contracts and solicitations. The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency.

"We reviewed the science, listened to the experts, and acted," said HHS Secretary Robert F. Kennedy, Jr. "BARDA is terminating 22 mRNA vaccine development investments because the <u>data</u> show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate."

The wind-down affects a range of programs including:

- Termination of contracts with Emory University and Tiba Biotech.
- De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Segirus.
- Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others, as part of BARDA's Rapid Response Partnership Vehicle (RRPV) and VITAL Hub.
- Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca, HDT Bio, and Moderna/UTMB.

While some final-stage contracts (e.g., Arcturus and Amplitude) will be allowed to run their course to preserve prior taxpayer investment, no new mRNA-based projects will be initiated. HHS has also instructed its partner, Global Health Investment Corporation (GHIC), which manages BARDA Ventures, to cease all mRNA-based equity investments. In total, this affects 22 projects worth nearly \$500 million. Other uses of mRNA technology within the department are not impacted by this announcement.

"Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That's why we're moving beyond the limitations of mRNA and investing in better solutions," said Secretary Kennedy.

The move signals a broader shift in federal vaccine development priorities. Going forward, BARDA will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices. Technologies that were funded during the emergency phase but failed to meet current scientific standards will be phased out in favor of evidence-based, ethically grounded solutions – like whole-virus vaccines and novel platforms.

<u>Statement from Leading Physician Groups on HHS Decision to Pull mRNA Vaccine</u> Funding

August 7, 2025

The statement below is issued by the:

American Academy of Family Physicians,

American Academy of Pediatrics,

American College of Obstetricians and Gynecologists,

American College of Physicians and the

American Osteopathic Association:

Our organizations, representing over 500,000 physicians and medical students, are dismayed and alarmed by the decision to halt most federal investment in mRNA vaccine research. This act stifles scientific innovation and our country's ability to react swiftly to future pandemics and public health emergencies—putting millions of lives at risk.

Sustained research funding is essential to developing the next generation of tools that protect Americans from infectious disease. Thanks to decades of rigorous science, testing and monitoring systems, vaccines used in the U.S. continue to be safe, effective and save lives.

We remain resolute in our support for investments in public health research and programs that prevent debilitating and fatal diseases and advance U.S. health care.

NIH [to 02 Aug 2025] http://www.nih.gov/ News Releases No new digest content identified

FDA

Press Announcements

FDA Begins Real-Time Reporting of Adverse Event Data

August 22, 2025

Today, the U.S. Food and Drug Administration began daily publication of adverse event data from the FDA Adverse Event Reporting System (FAERS). This represents a significant step forward in modernizing the agency's safety monitoring infrastructure and demonstrates its commitment to radical transparency and real-time protection of public health...

CDC/ACIP [to 02 Aug 2025]

http://www.cdc.gov/media/index.html

Latest News

Statement from the U.S. Department of Health and Human Services

HHS Secretary Robert F. Kennedy, Jr. visited CDC headquarters in response to tragic gunfire attack August 11, 2025

ACIP Meetings [to 02 Aug 2025]

Next ACIP Meetings

:: August/September (dates TBD)

:: October 22-23

FDA VRBPAC

Advisory Committee Calendar

Advisory Committee Calendar has no meetings posted for this Advisory Committee

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

Advisory Committee Calendar has no meetings posted for this Advisory Committee

National Vaccine Program Committee (NVAC)

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

https://www.hrsa.gov/advisory-committees/vaccines/meetings

Next ACCV Meeting - TBD

MMWR Weekly

https://www.cdc.gov/mmwr/index2025.html

August 21, 2025 / No. 31

PDF of this issue

:: Respiratory Syncytial Virus Immunization Coverage Among Infants

<u>Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination — United States, October</u> 2023—March 2024

August 14, 2025 / No. 30

PDF of this issue

:: <u>Vaccination Coverage Among Adolescents Aged 13–17 Years — National Immunization Survey-Teen, United States, 2024</u>

August 7, 2025 / No. 29

PDF of this issue

:: <u>Emergency Department Survey of Vaccination Knowledge, Vaccination Coverage, and Willingness to Receive Vaccines in an Emergency Department Among Underserved Populations — Eight U.S. Cities, April—December, 2024</u>

:::::::

U.S. Congress
House of Representatives
U.S. Senate

No new digest content identified.

.....

Supreme Court, Federal Appellate Courts

Supreme Court Lets Trump Administration Cut N.I.H. Grants for Disfavored Research

The court's order was fractured, with the justices splitting over whether individual cancellations and the policy behind them could be challenged in a federal trial court.

The New York Times, Aug. 21, 2025 By Adam Liptak Reporting from Washington

In <u>a fractured ruling</u>, the Supreme Court on Thursday ruled by a 5-to-4 vote that the Trump administration could for now cancel more than \$780 million in grants from the National Institutes of Health that the government said had been intended to explore topics like diversity, equity and inclusion initiatives, "gender ideology" and vaccine hesitancy.

But a different five-justice majority let stand for now a lower court's ruling that the administration's underlying policy directing the cuts was probably unlawful and should be put on hold. Only Justice Amy Coney Barrett was in both majorities.

The court's order is not the last word, and the case will proceed in lower courts. The upshot of the scrambled ruling, subject to ongoing litigation, appears to be that grants already canceled will not be immediately reinstated but that recipients <u>may be able to sue in a specialized court</u>. Further cancellations may be barred.

In a concurring opinion, Justice Barrett wrote that challenges to individual grant terminations had probably been filed in the wrong court. But she said the challenge to the policy guidance had been filed in the correct court...

::::::::

U.S. Health Governance/Policy/Funding: Analysis, Initiatives, Tracking, Responses

:::::::

HHS Staff Response to the August 8th Attack

Public servants and allies are standing together to demand work environments free from violence, accountability for leaders and policymakers who put everyday Americans in danger, and public health leaders who tell the American people the truth.

[Webpage accessed 23 August 2025]

Subject: Centers for Disease Control and Prevention (CDC) and Agency for Toxic

Substances and Disease Registry (ATSDR) Workers' Response to the August 8th

Attack

Date: August 20, 2025

To: Secretary Robert F. Kennedy, Jr., and Members of the U.S. Congress

We, the undersigned, write to you with grave concern for America's health and security.

The violent August 8th attack on CDC's headquarters in Atlanta was not random. The attacker fired hundreds of rounds into buildings as the CDC workforce inside carried out its mission of serving the American people. The attack came amid growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization—and now, violence.

CDC is a public health leader in America's defense against health threats at home and abroad. When a federal health agency is under attack, America's health is under attack. When the federal workforce is not safe, America is not safe.

Health and Human Services Secretary Robert F. Kennedy, Jr., is complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information, including:

- :: Sowing public mistrust by questioning the integrity and morality of CDC's workforce, including CDC a "cesspool of corruption." /
- :: Terminating critical CDC workers in a <u>destroy-first-and-ask-questions-later ii</u> manner; wasting taxpayer money while creating dangerous gaps in areas like <u>infectious</u> <u>diseases detection, worker safety, and chronic disease prevention and response. iii</u> Many CDC workers who focused on issues such as injury *iv* and violence prevention *v* have been fired. These agency- wide staffing cuts have impacted CDC's <u>emergency preparedness and response efforts *vi*.</u>
- **:: Falsely claiming mRNA vaccines "failed to protect effectively"** *vii* during the COVID-19 pandemic and subsequently <u>canceling \$500 million in contracts for mRNA vaccine</u> <u>development *viii*</u>, possibly our best line of defense against another respiratory virus pandemic.
- **::** Undermining public health outbreak response by <u>falsely claiming the measles</u> <u>vaccine has not been "safety tested" and that protection "wanes very quickly" *ix* while promoting inappropriate prevention measures like vitamin Ax even as U.S. measles case numbers *xi* are at their highest in more than 30 years.</u>
- **::** <u>Disbanding the Advisory Committee on Immunization Practices (ACIP) xii</u> despite reassuring Senator Cassidy during his confirmation hearing that he would not change the process. The Secretary has reconstituted it with inadequately vetted members who lack appropriate expertise and whose recommendations have been <u>driven by ideology rather than science. xiii</u>
- :: Misusing data to <u>falsely claim childhood vaccines are the cause of autism xiv</u> despite decades of research xv demonstrating otherwise.

These dangerous and deceitful statements and actions have contributed to the harassment and violence experienced by CDC staff. To uphold his pledge to safeguard the health of the American public, by September 2, 2025, **we ask Secretary Kennedy to do the following:**

- 1. **Stop spreading inaccurate health information**: Cease and publicly disavow the ongoing dissemination of false and misleading claims about vaccines, infectious disease transmission, and America's public health institutions.
- 2. **Affirm CDC's scientific integrity:** Acknowledge and affirm that CDC's work is rooted in scientific, non-partisan evidence focused on improving the health of *every* American.
- 3. **Guarantee the safety of the HHS workforce:** Ensure that the HHS workforce can carry out its duties in an environment free from imminent threats of harm. This should include emergency procedures and alerts that are fully functional for all workers and taking vigorous action to remove high-profile online material targeting the federal workforce such as the widely seen "DEI watchlists."

The deliberate destruction of trust in America's public health workforce puts lives at risk. We urge you to act in the best interest of the American people—your friends, your families, and yourselves.

Finally, we wish to honor Officer David Rose, who made the ultimate sacrifice in giving his life to protect others, and we extend our deepest gratitude for his service.

We sign this declaration in our own personal capacities, on our personal time, and without the use of government equipment, as protected by our First Amendment rights. In addition to the named signers, we include anonymous signers and speak for countless others across HHS who share our concerns but who chose not to sign out of fear of retaliation and personal safety.

Signatories

Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry (ATSDR)

[Approx 250 "public signatures" [names/credentials]; approx 350 anonymous signatures]

We, the undersigned NIH employees, sign this letter in solidarity with our CDC colleagues. We also call on NIH Director, Jayanta Bhattacharya, to refrain from his dangerous politicization of mRNA vaccine technology.

[Approx 60 "public signatures" [names/credentials]; approx 110 anonymous signatures]

We, the undersigned HHS employees, sign this letter in solidarity with our CDC colleagues. [FDA/ASTP/ASPR/CMS: 7 total signatories; 4 public signatures]

Citations

i https://www.gbnews.com/politics/us/rfk-promises-clean-cesspool-corruption-cdc

ii https://abcnews.go.com/Politics/rfk-jr-announces-hhs-reinstating-programs-employees-cut/story

iii https://www.pbs.org/newshour/politics/layoffs-begin-at-hhs-agencies-responsible-for-research-tracking-disease-and-regulating-food

iv https://www.reuters.com/business/healthcare-pharmaceuticals/us-consumer-safety-agency-stop-collecting-swaths-data-after-cdc-cuts-2025-04-

 $16/\#: \sim : text = April\%2016\%20 (Reuters)\%20\%2D\%20 The, source\%20 familiar\%20 with\%20 the\%20 situation$

v http://publichealthnewswire.org/?p=shooting-at-cdc-also-an-attack-on-violence-prevention

vi https://www.cbsnews.com/amp/news/cdc-scraps-plan-to-help-texas-schools-curb-measles-more-layoffs-loom/

vii https://www.factcheck.org/2025/08/rfk-jr-justifies-cuts-to-mrna-vaccine-projects-with-falsehoods/

viii https://apnews.com/article/kennedy-vaccines-mrna-pfizer-moderna-1fb5b9436f2957075064c18a6cbbe3c9 ix https://www.nbcnews.com/health/kids-health/health-secretary-rfk-jr-measles-vaccine-falsely-claims-wanes-rcna200636

x https://www.aap.org/en/news-room/fact-checked/fact-checked-vitamin-a-does-not-prevent-measles

xi https://www.cdc.gov/measles/data-research/index.html

xii https://abcnews.go.com/Health/rfk-jr-removing-17-members-cdcs-vaccine-advisory/story

xiii https://oversightdemocrats.house.gov/sites/evo-subsites/democrats-oversight.house.gov/files/evo-media-document/2025-07-10.rg-rk-to-cdc-re-acip-and-vaccines.pdf

xiv https://www.annenbergpublicpolicycenter.org/factcheck-org-kennedy-cites-flawed-paper-in-bid-to-justify-vaccine-autism-link/

xv https://pubmed.ncbi.nlm.nih.gov/24814559/

.....

<u>The American Academy of Pediatrics Releases Its Own Evidence-Based Immunization</u> Schedule

Schedule includes updated AAP recommendations for vaccines for fall respiratory viruses August 19, 2025

[Editor's text bolding]

ITASCA, IL— As respiratory virus season approaches, the American Academy of Pediatrics has published an evidence-based immunization schedule that includes updated guidance for influenza, RSV, and COVID-19 immunizations for children and adolescents from birth to age 18.

The schedule, "Recommended Childhood and Adolescent Immunization Schedule: United States, 2025," was published Aug. 19, 2025 in the AAP Red Book Online, the Academy's clinical guidebook for infectious diseases prevention and treatment.

Since its founding in 1930, the American Academy of Pediatrics has been a <u>leading voice in vaccine recommendations</u>, **creating evidence-based guidance to support pediatricians in caring for children and families.** The schedule published Tuesday continues in this tradition.

It differs from recent recommendations of the Advisory Committee on Immunization Practices of the CDC, which was overhauled this year and replaced with individuals who have a history of spreading vaccine misinformation.

"The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children and adolescents," said AAP President Susan J. Kressly, MD, FAAP. "Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving."

The schedule represents formal recommendations from the AAP for routine immunizations for infants, children and adolescents against 18 diseases. The schedule published Aug. 19 includes updated recommendations for RSV, influenza, and COVID-19 immunizations for pediatric populations.

In addition to the updated recommendations for the three respiratory viruses, the schedule incorporates recent updates regarding pentavalent meningococcal vaccine, the starting age of the Human Papilloma Virus vaccine, and removal of a hepatitis vaccine that is no longer available.

"The AAP urges every insurer to cover all the vaccines that are included in this immunization schedule," Dr. Kressly said. "AAP is committed to working with our partners at the local, state and federal levels to make sure every child, in every community has access to vaccines." AAP will also publish parent-friendly immunization schedule on HealthyChildren.org.

.....

Vaccine Integrity Project - Fall Immunization Information

From Data to Decisions: The Evidence Base for 2025 Fall/Winter Immunizations

YouTube Presentation, , August 19, 2025. CIDRAP, U Minesota

As we prepare for the upcoming respiratory virus season, it is important to recognize that flu, COVID, and RSV will all play significant roles in the months ahead. Following a flu season with nearly 270 pediatric deaths, clear and trustworthy information is essential to guide immunization decisions. Vaccines remain one of our most effective tools for preventing severe illness and death, but that protection depends on people knowing when and why to get vaccinated and trusting the guidance that informs those choices.

The Vaccine Integrity Project assembled a team of experts in epidemiology, infectious diseases, and evidence review to look at the recently published body of publicly available data concerning vaccine safety and efficacy for flu, COVID, and RSV immunizations. During the live stream on August 19th, the scientific research team focused on the effectiveness and safety of COVID-19 and RSV immunizations in pregnant, pediatric, and immunocompromised populations, coupled with a panel-led Q&A session.

Meeting Materials Watch the RECORDING Presentation slides

Executive summary

From Data to Decisions: The Evidence Base for 2025 Fall/Winter Immunizations

Summary of Preliminary Findings

Key Findings

- Respiratory viruses, including influenza, COVID-19, and respiratory syncytial virus (RSV) pose a significant threat to the health of all populations studied in this review.
- This initial systematic review and meta-analysis reviewed the evidence for children, immunocompromised adults, and pregnancy, and searched for more than 15 severe adverse events of special interest.
- Immunizations are an effective tool to reduce health risks for all populations from flu, COVID, and RSV, and have a strong safety profile. The studies reviewed since the 2023/2024 Advisory Committee on Immunization Practices (ACIP) meeting found no significantly elevated safety risks from US-licensed immunizations for these conditions.

... Conclusions

This provides clinicians, pharmacists, and the American people access to the latest safety and effectiveness data to make informed decisions and guide conversations about flu, COVID-19, and RSV immunizations this fall. The American Academy of Pediatrics announced guidelines for children on August 19th, and additional immunization guidelines from medical societies are expected soon. The recorded meeting and slides are available on the Vaccine Integrity Project website; additional analyses of these data, including for the healthy adults, will be made available on the website, and a detailed manuscript with all populations is forthcoming.

[full text at title link above]

::::::::

Overview of President Trump's Executive Actions on Global Health

KFF/Kaiser Aug 15, 2025

Authors: Jennifer Kates, Josh Michaud, Kellie Moss, Lindsey Dawson, and Anna Rouw

This guide *Fact Sheet* provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts. This resource identifies each executive action, describes its purpose and actions taken, and outlines the implications and what happens next for each. The resource will be updated as needed.



Europe

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

<u>World Mosquito Day 2025: Europe sets new records for mosquito-borne diseases - ECDC supporting Member States in adapting to 'new normal'</u>

20 Aug 2025

<u>EU Health Task Force deploys ECDC experts to Sierra Leone to support the mpox outbreak response</u>

15 Aug 2025

Surveillance and monitoring

Communicable disease threats report, 16-22 August 2025, week 34

22 Aug 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 August 2025 and includes updates on Crimean-Congo haemorrhagic fever, dengue, West Nile virus infection, chikungunya virus disease, Oropouche virus disease, vaccine-derived poliovirus type 1 (cVDPV1) and the expert deployment to support the national response to the mpox clade IIb outbreak in Sierra Leone.

Surveillance and monitoring

Seasonal surveillance of dengue in the EU/EEA

22 Aug 2025

Update providing weekly overview of the countries and areas where dengue cases have been reported.

Surveillance and monitoring

Seasonal surveillance for chikungunya virus disease in the EU/EEA for 2025

22 Aug 2025

Update providing weekly overview of the countries and areas where chikungunya virus disease cases have been reported.

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news News & Press Releases No new digest content identified.

::::::

Africa

Africa CDC [to 02 Aug 2025] https://africacdc.org/

Press Releases, Statements [Selected]

Africa CDC Weekly Brief | 11 - 17 August 2025

Africa CDC Applauds First-Ever Malaria Treatment for Infants Under 5 kg

16 August 2025

...The new artemether-lumefantrin formulation for children was developed through a partnership between Novartis and the Medicines for Malaria Venture (MMV), under the PAMAfrica consortium, with co-funding from the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency.

Swiss drug regulators have approved the formulation, and rapid approvals are expected from the eight African countries under the Swiss agency's Marketing Authorisation for Global Health Products procedure...

Africa CDC Weekly Brief | 4 - 10 August 2025

11 August 2025

::::::

China CDC+

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 02 Aug 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [to 02 Aug 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-08-22 / No. 34

PDF of this issue

- :: <u>Vital Surveillances: Analysis of Service Utilization and Medication Adherence Among Attendees of HIV Nonoccupational Post-Exposure Prophylaxis Clinics China, 2022–2024</u>
- :: <u>Methods and Applications: Auxiliary Diagnostic Value of the Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis in People Living with HIV/AIDS Beijing Municipality, China, 2022–2024</u>
- :: <u>Preplanned Studies: Assessment of Intercultural Communication Competence for China Field</u> Epidemiology Training Program (CFETP) Trainees China, 2025

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [to 02 Aug 2025]

https://alleninstitute.org/news-press/

Recent News

News

First-ever Open Science Quest supports the next generation of scientists

Jul 31, 2025

The course offered career and technical education credits that counted for high school graduation and helped prepare students for the realities of...

BMGF - Gates Foundation [to 02 Aug 2025]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements

<u>Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered</u> Research and Innovation

Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally

August 4, 2025

CARB-X [to 02 Aug 2025]

https://carb-x.org/

News

08.20.2025

Baxiva joins CARB-X portfolio to advance vaccine against E. coli infections

CARB-X has awarded Baxiva US\$3M to develop its multivalent glycoconjugate vaccine to prevent extraintestinal pathogenic Escherichia coli (ExPEC) infections.

Chan Zuckerberg Initiative [to 02 Aug 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 02 Aug 2025]

http://cepi.net/

CEPI News, Blog

News

Landmark African-led research to map the extent of Rift Valley fever impact

The studies will help scientists figure out if trials assessing the efficacy of Rift Valley fever vaccines are possible.

20 Aug 2025

News

Leading science labs in Korea join world's largest vaccine testing network

5 Aug 2025

- :: KDCA and IVI join global group of laboratories set up to standardise assessment of new vaccines.
- :: Expansion of network to Korea could help the country more quickly respond to future outbreaks.
- :: CEPI set up the centralised group of labs in 2020 to respond to the COVID-19 pandemic.
- :: KDCA and IVI already working with CEPI on pandemic preparedness and response efforts.

CIDRAP – Vaccine Integrity Project

https://www.cidrap.umn.edu/vaccine-integrity-project

News, Reports, Viewpoints

Vaccine Integrity Project - Fall Immunization Information

From Data to Decisions: The Evidence Base for 2025 Fall/Winter Immunizations

YouTube Presentation, , August 19, 2025

CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 02

Aug 2025]

https://cioms.ch/

News; Publications; Events No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 02 Aug 2025]

https://www.darpa.mil/news

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 02 Aug 2025]

https://dndi.org/press/press-releases/

Press Releases

Press releases 22 Aug 2025

<u>DNDi receives Japan's Hideyo Noguchi Africa Prize 2025 for its work to develop new treatments for neglected diseases in Africa</u>

Duke Global Health Innovation Center [to 02 Aug 2025]

https://dukeghic.org/

News

No new digest content identified.

EDCTP [to 02 Aug 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 02 Aug 2025]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

European Vaccine Initiative [to 02 Aug 2025]

http://www.euvaccine.eu/ Latest News, Events

EVI begins clinical trial for promising malaria vaccine in Burkina Faso

This EVI-sponsored clinical trial of the full-length MSP1/GLA-SE vaccine candidate, reflects our commitment to innovation in Aug 14, 2025

Fondation Merieux [to 02 Aug 2025]

http://www.fondation-merieux.org/ News, Events No new digest content identified.

Gates Medical Research Institute [to 02 Aug 2025]

https://www.gatesmri.org/news

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications No new digest content identified.

Gavi [to 02 Aug 2025] https://www.gavi.org/ Press Releases 13 August 2025

Guinea introduces malaria vaccine into routine immunization

GE2P2 Global Foundation [to 02 Aug 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review May 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 25 May 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest May 2025

GHIT Fund [to 02 Aug 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 02 Aug 2025]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 02 Aug

2025]

https://www.glopid-r.org/

No new digest content identified.

Hilleman Laboratories [to 02 Aug 2025]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 02 Aug 2025]

https://www.hhmi.org/news

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 02 Aug 2025]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [to 02 Aug 2025]

https://www.iavi.org/

Press Releases, Features

Press Releases

Phase 1 clinical trial of HIV vaccine starts in Africa to evaluate immune responses to highly networked HIV T-cell epitopes

August 4, 2025

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

INSERM [to 02 Aug 2025]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news

Selected Statements, Press Releases, Research

7 August 2025

Update - Reference documents added for PQKM Collaborative Hybrid Inspection Pilot

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 02 Aug 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selected]

7 August 2025

ICH Q3E Draft Guideline is Available Now on the ICH Website

The ICH Q3E draft "Guideline for Extractables and Leachables" and supporting document has reached Step 2b of the ICH Process on 1 August 2025 and entered the Step 3 public consultation period.

Ongoing Publ	ic Consultations	^
> MI3B EWG	Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
> Q1 EWG	Stability Testing of Drug Substances and Drug Products	
> M4Q(R2) EWG Revision of M4Q(R1)		
> E21 EWG	Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials	
> Q3E EWG	Guideline for Extractables and Leachables	
∨ E20 EWG	Adaptive Designs for Clinical Trials	

https://www.ich.org/page/public-consultations

E20 EWG Adaptive Designs for Clinical Trials

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Following MC approval in June 2025 the E20 Guideline title was changed to "Adaptive Designs for Clinical Trials"

Rapporteur: Dr. Gregory Levin (FDA, United States) Regulatory Chair: Dr. Christian Roes (EC, Europe) Date of Step 2b: 25 June 2025 Status: Step 3

Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025 EC, Europe - Deadline for comments by 30 November 2025 Health Canada, Canada - Deadline for comments by 25 September 2025 MHRA, UK - Deadline for comments by 30 November 2025 Swissmedic, Switzerland - Deadline for comments by 30 November 2025 TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

ICRC [to 02 Aug 2025] https://www.icrc.org/en/news

News

<u>Philippines: ICRC president highlights need to make international humanitarian law a political priority to support peace and stability</u>

22-08-2025 Manila (ICRC) – Mirjana Spoljaric, president of the International Committee of the Red Cross (ICRC), emphasised the critical role of international humanitarian law (IHL) in alleviating ... News release 22-08-2025

<u>Israel and the occupied territories: Intensification of hostilities threatens to worsen catastrophic humanitarian conditions in Gaza</u>

Statement from Julien Lerisson, Head of Delegation in Israel and the occupied territories "The civilian population in Gaza is living in abhorrent conditions. Further displacement and an ... Statement

21-08-2025

"A grave betrayal of humanity": Abhorrent attacks on aid workers must stop

This statement on World Humanitarian Day is attributed to Kate Forbes, president of the International Federation of Red Cross and Red Crescent Societies, and Mirjana Spoljaric, president of the ...

Statement

19-08-2025

<u>ICRC president: "International humanitarian law only as strong as leaders' will to uphold it"</u>

Speech given by Mirjana Spoljaric, president of the International Committee of the Red Cross, on 18 August 2025 in Bangkok, Thailand and the 11th HRH Princess Maha Chakri Sirindhorn Lecture on ... Statement

18-08-2025

IFFIm [to 02 Aug 2025]

http://www.iffim.org/

Press Releases/Announcements

In Kenya, a decade of rotavirus vaccination translates to a drop in childhood mortality 04 Aug 2025

Not only are fewer children being hospitalised with severe diarrhoea, but the vaccine's evident impact is boosting confidence in immunisation generally, experts say.

By Joseph Maina

IFRC [to 02 Aug 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press releases

Press release 20/08/2025

Malnutrition Crisis Northwest Nigeria

Press release 19/08/2025

IFRC launches Zero Hunger Campaign to drive durable food security across Africa

Press release 07/08/2025

Crisis to Resilience: Supporting Mongolia's herder families one year on

IPPS - International Pandemic Preparedness Secretariat [to 02 Aug 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

Institut Pasteur [to 02 Aug 2025]

https://www.pasteur.fr/en/press-area

Press Documents

No new digest content identified.

ISC / International Science Council [to 02 Aug 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

https://iuis.org/

News/Events [Selected]

No new digest content identified.

IVAC [to 02 Aug 2025]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 02 Aug 2025]

http://www.ivi.int/

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 02 Aug 2025]

https://centerforhealthsecurity.org/newsroom

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 02 Aug 2025]

http://www.msf.org/

Latest [Selected Announcements]

Gaza-Israel war

<u>Israeli authorities are starving Palestinians of water in Gaza</u>

Press Release 21 Aug 2025

Mozambique

Violence in Cabo Delgado sparks new wave of mass displacement as needs surge

Press Release 21 Aug 2025

Conflict in Sudan

Sudan: MSF suspends activities at Zalingei hospital following armed attack

Press Release 19 Aug 2025

Syria

New MSF programme treats survivors of detention in Syria

Project Update 18 Aug 2025

Gaza-Israel war

Gaza: Israel threatens to ban major aid organisations as starvation deepens

Open Letter 14 Aug 2025

Gaza-Israel war

"Medicine is being strangled": An MSF doctor on collapse of Gaza's healthcare system

Voices from the Field 14 Aug 2025

Conflict in Sudan

War fuels cholera outbreak across Sudan with MSF seeing over 2,300 patients and 40 dead

in one week

Press Release 14 Aug 2025

Central American migration

Unwelcome: Devastating impacts of new migration policies in the Americas

Report 12 Aug 2025

Central American migration

Dehumanising migration policies leave people abandoned in the Americas

Press Release 12 Aug 2025

Somalia

Funding gaps undermine healthcare for women and children in Somalia

Project Update 11 Aug 2025

Gaza-Israel war

This is not aid. This is orchestrated killing.

Report 7 Aug 2025

Gaza-Israel war

GHF-run food distributions in Gaza are sites of "orchestrated killing"

Press Release 7 Aug 2025

Democratic Republic of Congo

Fleeing conflict, facing crisis: South Sudanese refugees gather in Ituri, DRC

Project Update 6 Aug 2025

Ethiopia

Aid cuts threaten refugee lives in Ethiopia's Gambella region

Press Release 6 Aug 2025

Chad

Redefining healthcare: when communities lead the way in Chad

Documentary 5 Aug 2025

South Sudan

MSF suspends activities in two South Sudan counties after second abduction

Press Release 5 Aug 2025

National Academy of Medicine - USA [to 02 Aug 2025]

https://nam.edu/programs/ News, Stories, Insights Aug 20, 2025 Announcement

National Academy of Medicine Launches New Series to Help the Public Navigate Complex Health Debates; First Event Will Cover Ultra-Processed Foods and Children's Health

Aug 12, 2025 *News*

Monica Bertagnolli Nominated to Be Next National Academy of Medicine President

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 02 Aug 2025]

https://www.nationalacademies.org/newsroom

News

<u>Federal Leaders Should Respect and Safeguard the Integrity of Data from Government</u> Statistical Agencies

Statement | August 8, 2025

Federal statistics are vital to public policy and essential to the nation's economic well-being. Businesses, investors, and governments at all levels rely on trustworthy data to assess conditions, allocate resources, and make plans. The ability of federal statistical agencies to produce objective and credible information — free from political or other undue influence — is critical to effective decision-making, as well as to public trust in government.

For over 50 years, the National Academies of Sciences, Engineering, and Medicine's Committee on National Statistics has evaluated and guided federal statistical programs and methods across administrations of both parties. Since 1992, it has issued a regularly updated <u>report</u> articulating the core principles and practices that enable statistical agencies to fulfill their mission with integrity and efficacy. Among those principles is that statistical agencies must execute their missions without being subject to pressures to advance any political or personal agenda.

We urge federal leaders to respect and safeguard the integrity and objectivity of our federal statistical agencies and the information they produce, and to uphold the professional standards and statutory protections that allow these agencies to serve the nation effectively, impartially, and in the public interest.

Marcia McNutt

President, National Academy of Sciences

Victor J. Dzau

President, National Academy of Medicine

PATH [to 02 Aug 2025]

https://www.path.org/media-center/

Newsroom [Selected]

<u>Unitaid announces two new flagship investments to boost regional manufacturing of diagnostics and medicines in Africa</u>

Unitaid is making a foundational investment of nearly US\$ 50 million in two flagship programs aimed at strengthening the ability of countries in Africa to produce their own medical tests and treatments. August 21, 2025

Sabin Vaccine Institute [to 02 Aug 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

UNAIDS [to 02 Aug 2025] http://www.unaids.org/en News, Stories, Updates No new digest content identified.

UNICEF [to 02 Aug 2025]

https://www.unicef.org/media/press-releases Latest press releases, news notes and statements [Selected] Press release 22 August 2025

Famine confirmed for first time in Gaza

ROME/GENEVA/NEW YORK, 22 August 2025 –, More than half a million people in Gaza are trapped in famine, marked by widespread starvation, destitution and preventable deaths, according to a new https://www.ipcinfo.org/ Integrated Food Security Phase Classification (IPC) analysis released today. Famine conditions are ...

Press release 13 August 2025

<u>Urgent action is needed as humanitarian needs of children and families in As-Sweida continue to surge</u>

DAMASCUS, 13 August 2025, – The impact of recent violence in Syria's As-Sweida Governorate in July and early August continues to affect children and families. The violence, which reportedly left at least 22 children killed and 21 more injured, also caused significant damage to civilian infrastructure and further complicated the humanitarian response efforts. During the...

Statement 10 August 2025

With millions returning to Afghanistan, UNICEF calls for a safe, dignified, voluntary and phased approach and increased support for children and families

KABUL/NEW YORK, 9 August 2025 –, "I have just concluded my visit to Afghanistan, where over two million Afghans, including half a million children, have returned from Iran and Pakistan so far this year alone, in addition to a significant number from countries in Central Asia. "This was my fourth time in Afghanista...

Remarks 05 August 2025

Children in Sudan 'reduced to skin and bones' as UNICEF calls for urgent action

GENEVA/PORT SUDAN, Sudan, 5 August 2025, – "Over the past week, I travelled from Port Sudan to Aj Jazeera and Khartoum States, witnessing the impact that this crisis – the world's largest humanitarian crisis – is having on children and families. "During the mission, I saw homes, houses, and buildings destroyed. ...

Unitaid [to 02 Aug 2025]

https://unitaid.org/

News

News releases

<u>Unitaid announces two new flagship investments to boost regional manufacturing of diagnostics and medicines in Africa</u>

21 August 2025

... The first program, <u>Manufacturing to Accelerate Diagnostic Excellence (MADE)</u>, led by <u>PATH</u> in collaboration with a consortium of partners, will receive US\$11 million to help the most promising African companies develop high-quality diagnostic tests and scale up production so they can enter regional and global markets. This includes improving access to raw materials and helping manufacturers produce more of the input materials they need themselves, so they can control a greater share of their supply chains and the associated costs.

The second program, <u>Medicines Supply Resilience (MedSuRe) Africa</u>, led by <u>USP</u> and its consortium partners, will receive US\$35.5 million from Unitaid to boost the availability of essential medicines, including treatments for HIV, malaria, and postpartum hemorrhage. The program will work with African manufacturers to produce active pharmaceutical ingredients – the building blocks of medicines – as well as finished pharmaceutical products. It will also support the production of calibrated drapes, simple but highly effective tools for measuring blood loss during childbirth and helping to prevent deaths from postpartum hemorrhage. To ensure products meet the highest quality and regulatory standards, the program will build regional capacity for Clinical Research Organizations to conduct the necessary bioequivalence testing. As part of this package, the Medicines Patent Pool will also receive US\$1.5 million for complementary work...

News releases

<u>Unitaid and Jhpiego launch US\$26.5 million initiative to curb rising antimalarial drug resistance in Africa</u>

19 August 2025

Vaccine Equity Cooperative [nee Initiative] [to 02 Aug 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccine Confidence Project [to 02 Aug 2025]

http://www.vaccineconfidence.org/ News, Research and Reports

Vaccine Education Center – Children's Hospital of Philadelphia [to 02 Aug 2025]

http://www.chop.edu/centers-programs/vaccine-education-center
News

August 2025 — Aluminum in vaccines: Is it safe?

Dr. Paul Offit talks about aluminum, why it is in vaccines, and whether it's safe. He explains that aluminum serves as an adjuvant to boost the immune response to some vaccines. This in turn allows for using fewer doses and lesser quantities of the vaccine.

Wellcome Trust [to 02 Aug 2025]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified.

The Wistar Institute [to 02 Aug 2025]

https://www.wistar.org/news/press-releases

Press Releases August 19, 2025

The Wistar Institute Receives \$17 Million NIH Grant for Personalized HIV Cure Research

The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, \$17 million research award to launch iCure Consortium to develop individualized "cure regimens" for HIV.

World Bank [to 02 Aug 2025]

http://www.worldbank.org/en/news/all

All News [Selected]

<u>Protecting Women and Girls in the Democratic Republic of Congo (DRC) Against Cervical</u> Cancer

Date: August 19, 2025 Type: Feature Story

- :: DRC revises national cancer strategy, prioritizing HPV vaccine for girls.
- :: Over 7,700 women diagnosed yearly; >70% die from preventable cervical cancer.
- :: Global support drives HPV rollout, raising awareness & access to care.

WFPHA: World Federation of Public Health Associations [to 02 Aug 2025]

https://www.wfpha.org/

Blog, Events

No new digest content identified.

World Medical Association [WMA]_[to 02 Aug 2025]

https://www.wma.net/news-press/press-releases/

Press Releases

World Humanitarian Day: Health professionals on the brink as conflicts intensify

19th August 2025

Geneva, Switzerland: 19 August 2025—On World Humanitarian Day, WHPA, which represents 42 million health professionals, together with humanitarian organizations is sounding the alarm: life-saving health services—already underfunded and overstretched—are facing unprecedented pressure as conflicts intensify, targeted attacks on health facilities multiply, and funding is cut...

World Organisation for Animal Health [OIE] [to 02 Aug 2025]

https://www.oie.int/

Press Releases, Statements

Statements

New World screwworm continues to spread: WOAH calls for strong collaboration across livestock sectors and borders

Published on 22 August 2025

The World Organisation for Animal Health (WOAH) acknowledges the continuous spread of <u>New World screwworm</u> (NWS) (*Cochliomyia hominivorax*) in the Americas. Since its resurgence in Central America, first notified by Panama in June 2023, the disease has now been reported in Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Mexico, with more than 20, 000 new outbreaks reported in the World Animal Health Information System (WAHIS).

The prevention and control of this parasitic zoonotic disease that poses a serious threat to animals, humans, and the environment, is challenging and requires long-term coordinated efforts by affected and at-risk countries. Recognising this need, and acknowledging the ongoing work undertaken by countries and regional partners, the Global Framework for Progressive Control of Transboundary

Animal Diseases (GF-TADs) mechanism has been mobilised in the Americas through a <u>standing group</u> of experts on screwworm to facilitate experience and knowledge sharing...

::::::

ARM [Alliance for Regenerative Medicine] [to 02 Aug 2025]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest announcements identified.

BIO [to 02 Aug 2025]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 02 Aug 2025]

http://www.dcvmn.org/ News; Upcoming events No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 02 Aug 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [to 02 Aug 2025]

https://ifpma.org/

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 02 Aug 2025]

https://www.iapo.org.uk/news
Press and media [Selected]
No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [to 02 Aug 2025]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

<u>Press Releases</u> - No new digest announcements identified.

Bavarian Nordic

<u>Latest News</u> - No new digest announcements identified.

BioCubaFarma - Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

<u>News</u> - No new digest announcements identified.

BioNTech

Press Releases

8 August 2025

<u>BioNTech Reaches Agreement to Receive a Non-exclusive License for mRNA-based COVID-</u> 19 and/or Influenza Products and Resolve Patent Litigation with CureVac and GSK

Boehringer

<u>Press Releases</u> - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

<u>Latest News</u> - No new digest announcements identified.

CinnaGen

<u>Recent News</u> - No new digest announcements identified.

Clover Biopharmaceuticals – China

<u>News</u> - No new digest announcements identified.

Curevac

News

August 8, 2025

CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech

Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

08 Aug 2025

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation

:: CureVac will make an upfront settlement of \$370 million to GSK

:: GSK will receive a 1% royalty on future Pfizer / BioNTech US sales of influenza, COVID-19 and related combination mRNA vaccine products

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

<u>Home</u> - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

<u>News releases</u> - No new digest announcements identified.

Nanogen

<u>News</u> - No new digest announcements identified.

Novartis

<u>News</u> - No new digest announcements identified.

Novavax

<u>Press Releases</u> - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

https://rpharm-us.com/index.php

[No news or media page identified]

Sanofi Pasteur

<u>Press Releases</u> - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

<u>Press Releases</u> - No new digest announcements identified.

SK Biosciences

Press Releases

SK bioscience Discusses Collaboration with the Gates Foundation to Advance Global Health

Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea...

2025.08.21

SK bioscience Launches RSV Awareness Campaign at BeFe Baby Fair

Company runs promotional booth on RSV disease awareness during the event at COEX, Seoul.Parents of y... 2025.08.14

Takeda

Newsroom - No new digest announcements identified.

Valneva

<u>Press Releases</u> August 18, 2025

<u>Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged</u>
12 and Older

August 7, 2025

<u>Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine</u>
<u>IXCHIQ® in Elderly and Updates to the Prescribing Information</u>

Vector State Research Centre of Viralogy and Biotechnology

Home - [Website not responding [404 error]]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 2 https://www.tandfonline.com/toc/uabr21/current [Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 8: E541-627

https://journalofethics.ama-assn.org/issue/existential-health-care-ethics

Existential Health Care Ethics

The American Medical Association declares that physicians will address "natural and man-made assaults on the health and wellbeing of humankind," and that "[h]umanity is our patient." The World Medical Association likewise pledges physicians "to the service of humanity." This theme issue considers that, if these are to be more than mere assertions, we must think more powerfully than we have in the past about what continued human existence requires of global and domestic health care.

As an emerging area of moral philosophical inquiry concerned with human extinction, existential health care ethics considers the nature and scope of what health professionals and health professions are obliged to do—as individuals and collectives—to orient us to threats that undermine humanity's survival. Such threats include familiar ones like critical resource depletion and weapons of mass destruction proliferation and less familiar ones like planetary-scale anthropogenic disequilibrium of Earth systems and dual (military and civilian) use of technology applications.

American Journal of Human Genetics

Aug 07, 2025 Volume 112Issue 8 p1733-1980 https://www.cell.com/ajhg/current

This month in The Journal

Paul W. Hook, vSara B. Cullinan

The use of genomic testing for diagnostic purposes has increased as the cost of sequencing has decreased. However, genomic testing has been deployed mostly in pediatric settings with information on how it can benefit adult populations lacking. In this issue, Gold et al. assess the utility of sequencing for diagnostic purposes in a young adult (ages 18–40) population admitted to the intensive care unit (ICU). Through whole-exome sequencing, the authors discovered 24.4% of the 365 individuals in the cohort had a diagnostic variant.

American Journal of Infection Control

August 2025 Volume 53 Issue 8 p809-918 http://www.ajicjournal.org/current [Reviewed earlier]

American Journal of Preventive Medicine

August 2025 Volume 69 Issue 2 https://www.ajpmonline.org/current [Reviewed earlier]

American Journal of Public Health

August 2025 115(8) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 2 (Aug 2025)

https://www.ajtmh.org/view/journals/tpmd/113/1/tpmd.113.issue-2.xml

Perspectives

<u>The Threat of Avian Influenza in the Eastern Mediterranean Region: A One Health</u> Perspective

Mira Samer Alamer, et al.

DOI: https://doi.org/10.4269/ajtmh.24-0683

Page(s): 249–252

Review Articles

Antimicrobial Resistance in Sub-Saharan Africa: A Comprehensive Landscape Review

Valentina Totaro, et al.

DOI: https://doi.org/10.4269/ajtmh.25-0035

Page(s): 253–263

Annals of Internal Medicine

August 2025 Volume 178, Issue 8

https://www.acpjournals.org/toc/aim/current

Research and Reporting Methods

<u>Single-Arm Trials Can Provide Randomized Real-World Evidence: The Random Invitation Single-Arm Trial Design</u>

Perrine Janiaud, PhD, John P.A. Ioannidis, MD, DSc, Benjamin Kasenda, MD, PhD, ... et al.

Pages:1150-1156

Ideas and Opinions

<u>Preserving Scientific Integrity in Vaccine Policy: The Role of, and Risk to, the CDC's Advisory Committee on Immunization Practices</u>

Jason M. Goldman, MD and Sandra Adamson Fryhofer, MD

Pages:1197-1198

Artificial Intelligence – An International Journal

Volume 345 August 2025

https://www.sciencedirect.com/journal/artificial-intelligence/vol/345/suppl/C

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 02 Aug 2025) [No new digest content identified]

BMC Health Services Research

 $\underline{\text{http://www.biomedcentral.com/bmchealthservres/content}}$

(Accessed 02 Aug 2025

[No new digest content identified]

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 02 Aug 2025) [No new digest content identified]

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content (Accessed 02 Aug 2025)

<u>Motivations, acceptability and ethical considerations for interventional HIV cure research</u> at the end of life: perspectives from long-term survivors of HIV in the United States

Despite progress in antiretroviral therapy (ART), an effective cure for HIV remains out of reach. End-of-life (EOL) research studies involving individuals with a prognosis of six months or less offers an opportunity to advance cure science but has so far been limited to observational designs focused on HIV reservoirs. As interventional approaches at the EOL are now being considered, it is essential to assess their acceptability before moving forward. Understanding how long-term survivors (LTS) of HIV perceive these potential interventions, along with their motivations and ethical considerations, is critical to guiding the design of future EOL-HIV interventional research.

Authors: Ali Ahmed, Jeff Taylor, Whitney Tran, Simran Swaitch, Samuel O. Ndukwe, Rachel Lau, Kris H. Oliveira, Stephanie Solso, Cheryl Dullano, Andy Kaytes, Davey Smith, Robert Deiss, Sara Gianella and Karine Dubé

Citation: BMC Medical Ethics 2025 26:112

Content type: Research Published on: 23 August 2025

BMC Medicine

http://www.biomedcentral.com/bmcmed/content

(Accessed 02 Aug 2025)

<u>Evaluating the effectiveness of international travel controls to identify MPXV-infected travelers: a simulation study</u>

In August 2024, the World Health Organization (WHO) declared a public health emergency due to the rapid spread of mpox in Africa and beyond. International travel controls (ITCs), such as health screening and v...

Authors: Keisuke Ejima, Yuqian Wang, Akira Endo, Hiroaki Murayama, Yun Shan Goh, Alex R. Cook, Yong Dam Jeong, Shingo Iwami, Hyeongki Park, Borame Sue Lee Dickens, Shihui Jin, Jue Tao Lim, Conrad En Zuo Chan, Po Ying Chia, Barnaby E. Young, Yang Yang...

Citation: *BMC Medicine* 2025 23:473

Content type: Research Published on: 12 August 2025

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 02 Aug 2025) No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 02 Aug 2025)

<u>Factors affecting COVID-19 outcomes in Ireland: findings from a national database of 1,408,249 cases diagnosed between 2020 and 2022</u>

Serious outcomes of COVID-19 may include admission to an intensive care unit (ICU) or death. Multiple risk factors exist which may contribute to these outcomes. The aim of the study, employing a large national...

Authors: Shiraz Syed, Cecily Kelleher and Patricia Fitzpatrick

Citation: BMC Public Health 2025 25:2877

Content type: Research Published on: 21 August 2025

<u>Decoding vaccine hesitancy: a health belief model-driven comparative study of vaccination awareness dynamics in COVID-19 vaccination intentions</u>

The COVID-19 vaccination is a key strategy to control the pandemic; however, complex factors, including health awareness and social cognition, influence public intention to vaccinate. The Health Belief Model (...

Authors: Zeming Li and Xinying Sun Citation: BMC Public Health 2025 25:2865

Content type: Research Published on: 21 August 2025

Adherence to national and international vaccine information sources and future pandemic preparedness among Iranian adults in the post-COVID-19 era

The effectiveness of public health efforts and vaccination campaigns depends on the level of trust that the population has, which in turn depends on the population's confidence in health information sources an...

Authors: Mehrdad Askarian, Alireza Ahmadkhani, Shahrokh Mousavi, Nazeem Muhajarine, Alireza

Sadeghi, Sadrollah Zarei, Nahid Hatam and Ehsan Taherifard

Citation: BMC Public Health 2025 25:2859

Content type: Research Published on: 20 August 2025

<u>Vaccine hesitation: attitudes of Turkish health worker parents towards adult and childhood immunisation</u>

This study aimed to evaluate the perceptions, attitudes, and beliefs of healthcare professionals who are also parents toward childhood vaccinations, as well as the sociodemographic and occupational factors ass...

Authors: Emre Çelik, Çağrı Emin Şahin, Mehmet Sait Değer and Zeynep Meva Altaş

Citation: BMC Public Health 2025 25:2857

Content type: Research Published on: 20 August 2025

<u>Understanding the layout of emergency scientific research during COVID-19 prevention and control: a comparative analysis of project solicitation and project approval</u>

Emergency scientific research (ESR) is characterized by multidisciplinary integration, multidemand matching, and multiscenario application, which impose greater applicability requirements and tolerance for cos...

Authors: Jida Liu, Yuxin Wang, Yuwei Song and Qiaoqiao Li

Citation: BMC Public Health 2025 25:2687

Content type: Research Published on: 7 August 2025

The role of religious leaders in the acceptance of COVID-19 vaccinations: a systematic review

The development of COVID-19 vaccines was progressing rapidly, but vaccination acceptance posed many challenges in different communities. This study systematically reviewed the impact of religious leaders on th...

Authors: Rahim Ali Sheikhi, Mohammad Heidari and Pardis Doosti

Citation: BMC Public Health 2025 25:2683

Content type: Systematic Review Published on: 6 August 2025

<u>Parental and step-parental attitudes toward childhood vaccination in Kaduna State of Nigeria: a health belief model approach</u>

Childhood vaccination is a crucial public health intervention that prevents the spread of vaccinepreventable diseases and reduces childhood morbidity and mortality. However, vaccine hesitancy and low immuniza...

Authors: Maryam Mukhtar Sahabi, Zahra Amrollah Majdabadi, Reza Negarandeh and Sarieh Poortaghi

Citation: BMC Public Health 2025 25:2664

Content type: Research Published on: 6 August 2025

One year on - the long-term impact of COVID-19 pandemic and government restrictions on the health-seeking behaviour, financial security and mental health of TB survivors

People with tuberculosis (TB) may face long-term physical and psycho-social-economic disability related to TB treatment. The Corona Virus Disease 2019 (COVID-19) pandemic and government restrictions disrupted ...

Authors: Nelly Jinga, Kamban Hirasen, Olena Ivanova, Andrea Rachow, Salome Charalambous, Knut

Lönnroth, Aneesa Moolla, Mohammed Rassool and Denise Evans

Citation: BMC Public Health 2025 25:2660

Content type: Research Published on: 6 August 2025

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 02 Aug 2025) [No new digest content identified]

BMJ Evidence-Based Medicine

August 2025 - Volume 30 - 4 https://ebm.bmj.com/content/30/4 [Reviewed earlier]

BMJ Global Health

July 2025 - Volume 10 - 7 https://gh.bmj.com/content/10/7 [Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - May 2025 https://thebulletin.org/magazine/2025-03/ [Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 8, August 2025, 465-516 https://www.who.int/publications/journals/bulletin/ Articles

Collateral damage from violent incidents: human costs of polio immunization

Kamran Badizadegan, Kimberly M Thompson

Bull World Health Organ. 2025 Aug 1; 103(8): 484-492. Published online 2025 Jun 10.

doi: 10.2471/BLT.25.293307 PMCID: PMC12321238

Abstract Objective

To provide observational statistics on reported violent incidents, deaths and injuries associated with polio immunization activities in the context of global polio eradication efforts.

Methods

We made a systematic search of registries dedicated to documenting violence against health workers, as well as online news reports related to targeted attacks against polio immunization activities. Findings

We identified 362 violent incidents between 1998 and 2024 that reported 359 deaths, 358 non-fatal injuries and 179 kidnappings associated with polio immunization activities. Incidents included attacks on immunization facilities, workers, support staff (for example, security and transportation) and/or vaccine recipients, which also sometimes involved family members of vaccinees or uninvolved bystanders. The reported incidents occurred in 14 countries. The two countries still endemic for wild poliovirus transmission as of 2025 accounted for 85% (607/717) of the total deaths and injuries: Pakistan 69% (497/717) and Afghanistan 15% (110/717). Of the deaths and injuries reported, 47% (404/857) were vaccine delivery personnel, including individuals identified as volunteers, workers or staff and 28% (236/857) were security personnel. The total number of violent incidents peaked in 2014 (51 incidents, 64 deaths and 56 injuries), followed by 2024 (42 incidents, 40 deaths and 63 injuries), which are double the average of the preceding 5 years.

Conclusion

We found substantial human costs associated with the polio immunization activities conducted to achieve the goal of global polio eradication. Efforts are needed to find effective solutions to protect individuals on the frontline of polio immunization activities, particularly in places where the risks are highest.

Advancing humanitarian assistance amid adversity in 2025

Abdullah A Al Rabeeah, Shahul Ebrahim, Barrak Alahmad, Abdullah Almoallem, Ziad A Memish Bull World Health Organ. 2025 Aug 1; 103(8): 467–467A. Published online 2025 Aug 1.

doi: 10.2471/BLT.25.293672 PMCID: PMC12321239

Cell

Aug 21, 2025 Volume 188 Issue 17 p4475-4810 https://www.cell.com/cell/current [New edition; No digest content identified]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4 https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4 [Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 4 July 2025 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 3 Pages: 521-745 September 2025 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current Perspective

<u>US Food and Drug Administration's Advancing Real-World Evidence Program: Initial</u> Experience

<u>Kimberly A. Smith, Yin Huang, Theresa Kehoe, Stefanie Kraus, Mark Levenson, Jie Li, Kristen Miller, Ann Punnoose, Donna R. Rivera, Yuegin Zhao, Richard Forshee, John Concato</u>

Pages: 545-547

First Published: 27 April 2025

Clinical Therapeutics

August 2025 Volume 47Issue 8 p533-662 http://www.clinicaltherapeutics.com/current [New edition; No digest content identified]

Clinical Trials

Volume 22 Issue 3, June 2025 https://journals.sagepub.com/toc/ctja/22/3 Articles [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/

[Accessed 02 Aug 2025]

<u>Uptake of COVID-19 vaccine among female healthcare workers in Syria: results from a</u> 2022 cross-sectional survey

Healthcare workers play an important role in administering COVID-19 vaccines, particularly in conflict-affected settings. Syria has endured a protracted conflict for over a decade and while most of the healthc...

Authors: Zlatko Nikoloski, Elnur Aliyev, Robert Bain, Leonardo Menchini, Sahar Hegazi, Mai Zalkha,

Shaza Mouawad, Neha Kapil and Amaya Gillespie

Citation: Conflict and Health 2025 19:63

Content type: Research Published on: 18 August 2025

Contemporary Clinical Trials

Volume 155 August 2025 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/155/suppl/C [Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 4 / August 2025 https://www.liebertpub.com/toc/crispr/8/4 [Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025 https://link.springer.com/journal/40142/volumes-and-issues/13-1 [Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

August 2025 - Volume 38 - Issue 4 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 02 Aug 2025] [No new digest content identified]

Cytotherapy

August 2025 Volume 27 Issue 8 p885-1030 https://www.isct-cytotherapy.org/current [Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 2 Pages: 81-163 June 2025 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Development Policy Review

Volume 43, Issue 5 September 2025 https://onlinelibrary.wiley.com/toc/14677679/current Article

A critical approach to co-producing knowledge for development

Ryan Nehring, Fernando Galeana, Hilary Faxon e70025

First Published: 17 July 2025

DEBATE

The Prospects for International Development Cooperation in Times of Geopolitical Conflict and Resource Scarcity

André de Mello e Souza

e70029

First Published: 21 August 2025

DEBATE

<u>Taking (anti-)'woke' seriously: the future of development cooperation and humanitarian</u> aid

Emma Mawdsley, Glenn Banks, Chloe Sanyu, Regina Scheyvens, John Overton

e70031

First Published: 21 August 2025

When Empathy Fades: The Collapse of Humanitarian Responsibility in a Structurally Broken World

Carlos Lopes e70036

First Published: 21 August 2025

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

Disasters

Volume 49, Issue 3 July 2025 https://onlinelibrary.wiley.com/toc/14677717/current [Reviewed earlier]

eBioMedicine

Volume 117 July 2025 https://www.sciencedirect.com/journal/ebiomedicine/vol/117/suppl/C [Reviewed earlier]

EMBO Reports

Volume 26 Issue 16 22 August 2025 https://www.embopress.org/toc/14693178/current Editorial 31 July 2025

Student hostages in culture war

Bernd Pulverer

The US administration has extended its line of attack on academia from US federal research to private universities. The resulting abuse of international students is both ethically wrong and ultimately self-defeating.

Science & Society 31 July 2025

Fool's-gold science: The ethical and scientific perils of testing most vaccines using placebo-controlled randomized trials

Arthur Caplan, Felicia L Pasadyn, Nathaniel Mamo

The US Department of Health and Human Services' proposed imposition of placebo-controlled trials for testing most new and existing vaccines jeopardizes public health and puts trial participants at unnecessary and easily avoidable risks—a violation of both scientific and ethical standards.

Emerging Infectious Diseases

Volume 31, Number 7—July 2025 http://wwwnc.cdc.gov/eid/ [Reviewed earlier]

Epidemics

Volume 51 June 2025 https://www.sciencedirect.com/journal/epidemics/vol/51/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025 https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 4 Pages: 1-17 July–August 2025 https://onlinelibrary.wiley.com/toc/25782363/current

Sharing aggregate results :: Consent and health data

Articles

Revisiting the Obligation to Share Aggregate Results with Research Participants in the Era of Open Science

Katherine E. MacDuffie, Benjamin S. Wilfond, Stephanie A. Kraft

Pages: 29-36

First Published: 14 July 2025

Essay: Ethics in Translational Research

Reconsidering Open-Ended Consent for Biospecimen and Health Record Research in the United States and Europe

Mark A. Rothstein, Prabha Rajasekaran, Edward S. Dove

Pages: 43-50 First Published: 14 July 2025

Ethics & International Affairs

Volume 39 - Issue 1 - Spring 2025 https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 3, June 2025 https://academic.oup.com/eurpub/issue/35/3 [Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

July/August 2025 Volume 104, Number 4 https://www.foreignaffairs.com/issues/2025/104/4 [Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2 http://www.tandfonline.com/toc/sfds20/current

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities
[Reviewed earlier]

Frontiers in Genetics

https://www.frontiersin.org/journals/genetics
[Accessed 02 Aug 2025]

Review Published on 21 Aug 2025

A decade of research on genetic privacy: the findings of the GetPreCiSe Center at Vanderbilt University

Christopher Slobogin, et al. Frontiers in Genetics doi 10.3389/fgene.2025.1629386

Editorial Published on 20 Aug 2025

Editorial: Rare diseases research and diagnosis in low- and middle-income countries

Claudia Gonzaga-Jauregui, et al.

Frontiers in Genetics doi 10.3389/fgene.2025.1675361

Original Research Published on 07 Aug 2025

<u>From ownership to custodianship: rethinking human biospecimens data governance in the Chinese context</u>

Yifan Peng, et al. Frontiers in Genetics doi 10.3389/fgene.2025.1621739

Frontiers in Genome Editing

https://www.frontiersin.org/journals/genome-editing

[Accessed 02 Aug 2025]

Perspective Published on 20 Aug 2025

Ethical dimensions and societal implications: ensuring the social responsibility of CRISPR technology

Irfan Biswas

Frontiers in Genome Editing doi 10.3389/fgeed.2025.1593172

Frontiers in Medicine

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463

[Accessed 02 Aug 2025]

Editorial Published on 12 Aug 2025

Editorial: Regulatory science and meta science as components of regulation of medical products and practices

Barbara K. Redman, Christine Gispen-de Wied, Thalia Arawi Frontiers in Medicine doi 10.3389/fmed.2025.1664402

Gene Therapy – Nature

Volume 32 Issue 4, July 2025 https://www.nature.com/gt/volumes/32/issues/4 [New issue; No digest content identified]

Genetics in Medicines

Volume 27, Issue 6 June 2025 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 02 Aug 2025] [No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2025 | Volume 13 | Number 1 http://www.ghspjournal.org/content/current REVIEWS

Narrative Review of Human-Centered Design in Public Health Interventions in Low- and Middle-Income Countries: Recommendations for Practice, Research, and Reporting
Bee-Ah Kang, Manvi Poddar, Aditi Luitel, Rajiv N. Rimal, Biruk Melaku and Danielle Piccinini Black

Global Health: Science and Practice August 2025, 13(1):e2400164; https://doi.org/10.9745/GHSP-D-24-00164

Although human-centered design is increasingly used in global health, its comprehensive application in health programs remains underexplored. Our narrative review demonstrates design tools and strategies, research methods, and reporting patterns across the included studies to provide practical recommendations.

Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 02 Aug 2025]

Article

Israel: Digital Vaccination Registry Launched

On July 10, 2025, Israel launched a national vaccination registry. The registry is designed to consolidate all the information about the vaccinations a patient receives throughout their life that was previously recorded separately by various organizations. This information ranges "from maternity vaccines in the hospital, through the Tipat Halav [pediatric] clinics and the HMOs, through the ... Continue reading "Israel: Digital Vaccination Registry Launched"

Contributor: Levush, Ruth

Date: 2025-08-15

Global Public Health

Volume 20, Issue 1 (2025) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/

[Accessed 02 Aug 2025]

<u>In the aftermath of the adoption of the landmark Pandemic Accord: what are the strategic options for its effective implementation in Africa?</u>

Following three years of complex negotiations, the Intergovernmental Negotiating Body announced consensus among Member States on 16 April 2025, leading to the adoption of the Pandemic Accord at the Seventy-Eig...

Authors: Olushayo Oluseun Olu, Henry Bosa Kyobe, Robert Lubajo, Amos Petu, Abdulmumini Usman,

Sylvester Maleghemi and Francis Chisaka Kasolo Citation: *Globalization and Health* 2025 21:49

Content type: Comment Published on: 20 August 2025

The United States withdrawal from the world health organization (WHO), its implications for global health governance

On January 20, 2025, the United States initiated its withdrawal from the World Health Organization (WHO) through an executive order, citing concerns over the organization's handling of global health crises, po...

Authors: Stephen Olaide Aremu, Akyala Ishaku Adamu, Odinaka Kingsley Obeta, Donald Ofili Ibe,

Solomon Ambina Mairiga, Mojisola Ashiat Otukoya and Abdillahi Abdi Barkhadle

Citation: Globalization and Health 2025 21:48

Content type: Comment Published on: 12 August 2025

Beneath the rhetoric of global justice: Reinforcement of global hegemonic governmentality by South Korea's Global Vaccine Hub Project

During the coronavirus disease 2019 pandemic, the South Korean government initiated the Global Vaccine Hub Project (GVHP) purportedly to address global vaccine inequality. This study analyzes the strategies an...

Authors: Jimin Gim, Jiwon Park and Sun Kim Citation: *Globalization and Health* 2025 21:44

Content type: Research Published on: 9 August 2025

Health and Human Rights

Volume 26, Issue 2, December 2024 https://www.hhrjournal.org/volume-26-issue-2-december-2024/ **Special Section: Distress Migration and the Right to Health** [Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 1 - January 2025 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 6, July 2025 https://academic.oup.com/heapol/issue/40/6 [Reviewed earlier]

Health Research Policy and Systems

http://www.health-policy-systems.com/content [Accessed 02 Aug 2025] [No new digest content identified]

Human Gene Therapy

Volume 36, Issue 13-14 / July 2025 https://www.liebertpub.com/toc/hum/36/13-14 [Reviewed earlier]

Humanitarian Practice Network

https://odihpn.org/
[Accessed 02 Aug 2025]
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025

https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList

Selected Content [Reviewed earlier]

Immunity

Jul 08, 2025 Volume 58 Issue 7 p1615-1870 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/ [Accessed 02 Aug 2025] [No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content]
[Accessed 02 Aug 2025]
[No new digest content identified]

International Health

Volume 17, Issue 4, July 2025 https://academic.oup.com/inthealth/issue/17/4 [Reviewed earlier]

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025) https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml [Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 5 (2025): May 2025 https://www.ijcmph.com/index.php/ijcmph/issue/view/124 [Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025 https://academic.oup.com/ije/issue/54/3 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 2 2025 https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/2 Table of contents [Reviewed earlier]

JAMA

https://jamanetwork.com/journals/jama/currentissue

August 19, 2025, Vol 334, No. 7, Pages 555-650

Viewpoint

Priorities for a New FDA

Martin A. Makary, MD, MPH; Vinay Prasad, MD, MPH

JAMA. 2025;334(7):565-566. doi:10.1001/jama.2025.10116

This Viewpoint outlines new priorities of the US Food and Drug Administration (FDA).

August 12, 2025, Vol 334, No. 6, Pages 467-550

Research Letter

Characterization of Research Grant Terminations at the National Institutes of Health

Michael Liu, MPhil; Kushal T. Kadakia, MSc; Vishal R. Patel, MD, MPH; et al.

JAMA. 2025;334(6):534-536. doi:10.1001/jama.2025.7707

This study examines the impact of National Institutes of Health grant terminations on the US research enterprise by quantifying the number and funding amount of these terminations and characterizing their award type and institute or center.

Viewpoint

FDA Review of Novavax's COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice

Patricia J. Zettler, JD; Stephen Cha, MD, MHSR; Sarah Despres, JD; et al.

JAMA. 2025;334(6):479-480. doi:10.1001/jama.2025.9898

This Viewpoint notes that the review and communication processes for the Novavax COVID-19 vaccine deviated from standard practice and raises concerns if this is the "new normal" for the FDA.

The WHO Pandemic Agreement - The World Together Equitably

Lawrence O. Gostin, JD; Sam Halabi, JD, MPhil; Alexandra Finch, LLM

JAMA. 2025;334(6):481-482. doi:10.1001/jama.2025.9198

This Viewpoint describes the World Health Assembly's newly adopted Pandemic Agreement, which lays a framework for action including preventing zoonotic spillovers, health system preparedness, and equitable response, and discusses the ramifications of the absence of US participation in the agreement.

August 5, 2025, Vol 334, No. 5, Pages 375-462

Special Communication

SPIRIT 2025 StatementUpdated Guideline for Protocols of Randomized Trials

An-Wen Chan, MD, DPhil; Isabelle Boutron, MD, PhD; Sally Hopewell, DPhil; et al.

free access has active quiz

JAMA. 2025;334(5):435-443. doi:10.1001/jama.2025.4486

This Special Communication introduces the updated Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2025 statement, which includes substantive and structural changes to incorporate new evidence and emerging perspectives. *Editorial*

Surrogate End Points in Trials—SPIRIT and CONSORT Extensions

Rod S. Taylor, PhD; Anthony Muchai Manyara, PhD; Joseph S. Ross, MD, MHS; Oriana Ciani, PhD

Viewpoint

Pausing Chikungunya Vaccination and Accelerated Approval

Vinay Prasad, MD, MPH; David C. Kaslow, MD; Sixun Yang, MD, PhD

JAMA. 2025;334(5):385-386. doi:10.1001/jama.2025.9393

This Viewpoint discusses a safety communication recommending a pause in the use of live attenuated chikungunya virus vaccine.

<u>Termination of a Federal Infection Prevention Advisory Committee - Eroding Health Care</u> <u>Safety</u>

Thomas R. Talbot, MD, MPH; Michael Yen-Wei Lin, MD, MPH; Deborah S. Yokoe, MD, MPH; et al. JAMA. 2025;334(5):389-390. doi:10.1001/jama.2025.9289

This Viewpoint discusses the US Centers for Disease Control and Prevention's Healthcare Infection Control Practices Advisory Committee and how its termination could affect infection prevention standards in the future.

JAMA Health Forum

July 2025, Vol 6, No. 7 https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

July 2025, Vol 179, No. 7, Pages 691-810 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

July 2025 - Volume 23 - Issue 7 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

Journal of Adolescent Health

July 2025 Volume 77 Issue 1 p1-172 https://www.jahonline.org/current [Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025) https://www.jair.org/index.php/jair [Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 1 March 2025 https://link.springer.com/journal/11673/volumes-and-issues/22-1 [Reviewed earlier]

Journal of Community Health

Volume 50, Issue 3 June 2025 https://link.springer.com/journal/10900/volumes-and-issues/50-3 [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025 https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C [Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 3, July 2025 http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

Journal of Epidemiology & Community Health

July 2025 - Volume 79 - 7 https://jech.bmj.com/content/79/6 [Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 2 June 2025 https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 1 (2025) http://www.tandfonline.com/toc/rjge20/current [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 2, May 2025 https://muse.jhu.edu/issue/54734 Table of Contents [Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 4 August 2025 https://link.springer.com/journal/10903/volumes-and-issues/27-4 [Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 2 (2025) https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 37, Issue 5 Pages: 1-1193 July 2025 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Medical Ethics

July 2025 - Volume 51 - 7 http://jme.bmj.com/content/current [Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

The Journal of Pediatrics

Volume 282 July 2025 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1 https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList [Reviewed earlier]

Journal of Public Health Management & Practice

July/August 2025 - Volume 31 - Issue 4 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 2 June 2025 https://link.springer.com/journal/41271/volumes-and-issues/46-2 [Reviewed earlier]

Journal of the Royal Society – Interface

August 2025 Volume 22 Issue 229

https://royalsocietypublishing.org/toc/rsif/current

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 32, Issue 5, July 2025 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 99 • Number 6 • June 2025 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

https://www.thelanc et.com/journals/lancet/issue/current **Aug 23, 2025 Volume 406 Number 10505 p779-884** *Editorial*

RFK Jr and MAHA: dangerous, emboldened, and escalating

The Lancet

The week beginning Aug 4, 2025 was the most dangerous and tragic week of Robert F Kennedy Jr's tenure yet: a fatal CDC shooting by a gunman distrustful of COVID-19 vaccines, the cancellation of US\$500 million in mRNA research funding, and his malicious call to retract a peer-reviewed *Annals of Internal Medicine* paper on vaccine safety. RFK Jr has built an increasingly powerful movement in Make America Healthy Again (MAHA). Either through incompetence or disinformation, the actions of this movement pose the greatest threat to the health of Americans and millions of people globally.

Kennedy cited lack of effectiveness, mRNA COVID-19 vaccines encouraging mutations in the pandemic, and a 181-page document that led him to conclude that the risks outweighed the benefits in further researching the mRNA vaccine platform. Later that week, Jay Bhattacharya, National Institute of Health Director, argued that the cancellation was because of public mistrust. But even this scientifically illiterate act of self-sabotage did not satisfy some of the MAHA base who dwell in a world inverted, where the familiar words of trust, data, and transparency are systematically used to discredit, dismantle, and undermine scientific institutions and individuals.

First, to the science. Multiple large, robust, and peer-reviewed clinical studies have concluded that millions of lives were saved during the COVID-19 pandemic from mRNA vaccines. Not by stopping transmission, but by preventing severe disease, hospitalisation, and death. There is no evidence that mRNA vaccines increase the virus mutation rate. The 181-page bibliography that Kennedy refers to contains many small, non-peer-reviewed studies and carefully selected paragraphs that do not discuss empirical data or major findings. The mRNA vaccine platform is the most effective tool we have in pandemic preparedness. The rapid and transitory nature of mRNA-encoded proteins that do not need to enter the nucleus or risk genomic integration makes them promising tools for infectious and non-infectious diseases such as cancer. Several areas continue to need refinement including: storability, stability, duration of expression, and targetability. Further research might achieve this. Like any intervention, mRNA vaccines are not perfect. There are known adverse events—a large observational study of 298 792 852 doses of mRNA vaccines given during the first 6 months of the US COVID-19 vaccination programme found the rate of myopericarditis to be 4·4 per million doses, and that most adverse events were mild and short-lived. The public health community must continue to communicate these adverse events transparently and weigh the risks and benefits for each population.

Second, to trust. It is true that trust in public health was damaged during the COVID-19 pandemic and that many US citizens are concerned because of the discordance between the amount the US spends on health care per capita (about \$13 000) and the overall poor population health of Americans (the lowest life expectancy of any high-income country). It is understandable that the bold proclamations and blame that Kennedy and MAHA propagate may be seductive. Their movement is based on the premise that big pharma and big food profit from keeping Americans unhealthy. Undoubtedly there are many problems with an under-regulated US food system and a privatised health-care system. But a recent Pew Research Poll on who influences health policy and health priorities indicates that eight out of ten Americans agree that cancer, obesity, heart disease, and opioid addictions are key issues and that seven out of ten feel that health insurance companies are overly influential. Where then are the plans for universal health-care coverage or to regulate health insurance companies? To fund scientific endeavours to face these challenges? To regulate agriculture and the food environment? A second MAHA report is promised but as yet there is no indication that these plans will be proposed. Rather, Kennedy and some leaders of the MAHA movement choose to nurture mistrust through disinformation and misdirect genuine concerns to align with an anti-science and anti-vaccine agenda. Supported by a band of wellness industry entrepreneurs and influencers who sometimes directly profit from these diversions, this is an agenda that will do nothing for trust, science, or for health.

Although the health and science community must engage, and understand what has made this movement so beguiling, nobody should be under any illusions as to what it is—a dangerous pseudoscientific programme of work that supports a corrupt and unscientific wellness industry, seeks to discredit mainstream medicine, and portrays institutions and experts as enemies, not partners.

Viewpoint

Bioethics for the planet

Warwick Anderson, et al.

Severe threats to the health of humans and other species derive from degradation of Earth's life-support systems, particularly the impacts of climate change. Researchers and practitioners in clinical medicine, public health, global health, and One Health are increasingly focusing on these risks to planetary health, which include (but are not limited to) rising temperatures, extreme weather disasters, intensified wildfires and flooding, biodiversity and species loss, expansion of vectors of infectious diseases, reduction of arable land alongside growth of intensive and factory farming, a proliferation of microplastics, antimicrobial resistance, and chemical contamination of the environment. 1–5

Aug 16, 2025 Volume 406 Number 10504 p665-778

Comment

A crisis of credibility: the global cost of US vaccine misinformation

Heidi J Larson, Simon J Piatek

Aug 09, 2025 Volume 406 Number 10503 p571-664

Editorial

Holding nations accountable: strategic litigation for health

The Lancet

Comment

The famines in Gaza and other conflict areas are a moral failure Saskia Osendarp, et al.

The Lancet Child & Adolescent Health

Aug 2025 Volume 9 Number 8 p519-612, e16

https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Jun 2025 Volume 7 Number 6 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Jul 2025 Volume 13 Number 7 e1151-e1326 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Aug 2025 Volume 25 Number 8 p827-946, e439-e490 https://www.thelancet.com/journals/laninf/issue/current [Reviewed earlier]

Lancet Public Health

Jul 2025 Volume 10 Number 7 e537-e639 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Jul 2025 Volume 13 Number 7 p569-654, e33-e37 https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 6 June 2025 https://link.springer.com/journal/10995/volumes-and-issues/29-6 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 5, July 2025 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 2 Pages: 243-637 June 2025 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Aug 06, 2025 Volume 33 Issue 8 p3453-4008 https://www.cell.com/molecular-therapy/current [New issue; No digest content identified]

Nature

https://www.nature.com/nature/volumes/644/issues/8077

Volume 644 Issue 8077, 21 August 2025

Editorial 15 Aug 2025

Cancelling mRNA studies is the highest irresponsibility

The rest of the world is not following the US government's dangerous path, and will stick with the technology that helped the world out of the COVID-19 pandemic.

Volume 644 Issue 8076, 14 August 2025

Editorial 07 Aug 2025

Monoclonal antibodies revolutionized biomedical science and health care

The story of the discovery of these molecules 50 years ago shows how the free exchange of ideas can lead to life-changing treatments.

Comment 08 August 2025

Decolonize scientific institutions, don't just diversify them

Indigenous scholars set out eight steps to stop marginalization in academia and to enable a shared Indigenous agenda in science.

Tara G. McAllister, Leilani A. Walker, Kat Milligan-McClellan

Volume 644 Issue 8075, 7 August 2025

[New issue; No digest content identified]

Nature Biotechnology

Volume 43 Issue 7, July 2025 https://www.nature.com/nbt/volumes/43/issues/7 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 02 Aug 2025) [Reviewed earlier]

Nature Genetics

Volume 57 Issue 7, July 2025 https://www.nature.com/ng/volumes/57/issues/7 [Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 7, July 2025

https://www.nature.com/nathumbehav/volumes/9/issues/7

[Reviewed earlier]

Nature Medicine

Volume 31 Issue 7, July 2025 https://www.nature.com/nm/volumes/31/issues/7 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 7, July 2025 https://www.nature.com/nrd/volumes/24/issues/7 [Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 7, July 2025 https://www.nature.com/nrg/volumes/26/issues/7 [Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 7, July 2025 https://www.nature.com/nri/volumes/25/issues/7 [Reviewed earlier]

New England Journal of Medicine

https://www.nejm.org/toc/nejm/medical-journal

Volume 393 No. 8 August 21/28, 2025

Sounding Board

The Path Forward for Vaccine Policy in the United States

Helen Y. Chu, M.D., M.P.H., Noel T. Brewer, Ph.D., Edwin J. Asturias, M.D., Oliver Brooks, M.D., Sybil Cineas, M.D., Denise J. Jamieson, M.D., M.P.H., Mini Kamboj, M.D., +9, and Lin H. Chen, M.D. *Abstract*

The former members of the Advisory Committee on Immunization Practices consider paths forward for U.S. vaccine policy in the wake of their dismissal by the Secretary of Health and Human Services in June 2025.

Volume 393 No. 7 August 14, 2025

Perspective

Dismantling Public Health Infrastructure, Endangering American Lives

T.R. Frieden

Abstract

The extreme reductions that the Trump administration is making at the vital, mission-driven Centers for Disease Control and Prevention amount to unilateral disarmament against health hazards.

Volume 393 No. 6 August 7, 2025

Medicine and Society

Restoring the Infant Mortality Rate as a Measure of Societal Health and Well-Being

E.A. Harrison , U. Ndulue , and B.O. Ojikutu

NEJM Evidence

Volume 4 No. 7 July 2025

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 02 Aug 2025] [No new digest content identified]

Pediatrics

Volume 156, Issue 2 August 2025 https://publications.aap.org/pediatrics/issue/156/2 Feature

USAID's Role in Saving Children's Lives: Past Legacy and Future Directions

Alexandra L. Coria, MD, FAAP; Brian Wahl, PhD, MPH; Naveen Thacker, MD (Ped), FIAP; Rachel Vreeman, MD, MS, FAAP; Liesl Zühlke, MBChB, FCP, MPH, MSc, PhD

For more than 60 years, the US Agency for International Development (USAID) has been a major funder of efforts to improve maternal and child health (MCH) across many low- and middle-income countries (LMICs). From 2000 to 2023, the global under-5 mortality rate declined from 76.7 to 36.7 deaths per 1000 live births.¹ Although this progress stemmed from the cumulative efforts of many organizations, governments, and health care workers, a 2022 causal analysis by Weiss et al (the most recent analysis available), demonstrated that from 2000 to 2016, high USAID funding for MCH and malaria independently reduced under-5 mortality by more than 20 deaths per 1000 live births compared with control regions.²

However, death rates alone cannot capture the broader effects of promoting MCH. Healthy children become healthier, more productive adults, leading to more stable societies.^{3,4} Understanding USAID's impact requires examining the full spectrum of their...

From the American Academy of Pediatrics Policy Statement

<u>Medical vs Nonmedical Immunization Exemptions for Child Care and School Attendance:</u> Policy Statement

Jesse M. Hackell, MD, FAAP; Kyle Brothers, MD, PhD, FAAP; Sara Bode, MD, FAAP; Lisa M. Costello, MD, MPH, FAAP; Lisa M. Kafer, MD, FAAP ...

Routine childhood immunizations against infectious diseases are an integral part of our public health infrastructure. They provide direct protection to the immunized individual and indirect protection to children and adults unable to be immunized by reducing spread of vaccine-preventable diseases in the community. All 50 states, the District of Columbia, and Puerto Rico have regulations requiring proof of immunization as a condition for child care and school attendance as a public health strategy to protect children in these settings and to secondarily serve as a mechanism to promote timely immunization of children by their caregivers. Although all states and the District of Columbia have mechanisms to exempt school attendees from specific immunizations for medical reasons, the majority also have a heterogeneous collection of regulations and laws that allow nonmedical reasons for exemption. The American Academy of Pediatrics (AAP) supports certification of immunization to attend child care and school as a sound means of providing a safe environment for attendees and employees of these settings. The AAP also supports medically indicated exemptions to specific immunizations as

determined for each individual child. The AAP advocates for the elimination of nonmedical exemptions from immunizations as contrary to optimal individual and public health.

PharmacoEconomics

Volume 43, Issue 8 August 2025 https://link.springer.com/journal/40273/volumes-and-issues/43-8 [Reviewed earlier]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 02 Aug 2025) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 02 Aug 2025) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 02 Aug 2025)
[No new digest content identified]

PLoS Medicine

https://journals.plos.org/plosmedicine/ (Accessed 02 Aug 2025)

Reductions in development assistance for health funding threaten decades of progress in Africa

Peter MacPherson, Marriott Nliwasa, Augustine T. Choko Perspective | published 22 Aug 2025 PLOS Medicine https://doi.org/10.1371/journal.pmed.1004695

The potential impact of declining development assistance for health on population health in Malawi: A modelling study

Margherita Molaro, Paul Revill, Martin Chalkley, Sakshi Mohan, Tara D. Mangal, Tim Colbourn, Joseph H. Collins, Matthew M. Graham, William Graham, Eva Janoušková, Gerald Manthalu, Emmanuel Mnjowe, Watipaso Mulwafu, Rachel E. Murray-Watson, Pakwanja D. Twea, Andrew N. Phillips, Bingling She, Asif U. Tamuri, Dominic Nkhoma, Joseph Mfutso-Bengo, Timothy B. Hallett Research Article | published 21 Aug 2025 PLOS Medicine https://doi.org/10.1371/journal.pmed.1004488

<u>Current global practice and implications for future research on disseminating health</u> <u>research results to study participants: A systematic review</u>

Mary Bagita-Vangana, Holger W. Unger, Kamala Thriemer Research Article | published 14 Aug 2025 PLOS Medicine https://doi.org/10.1371/journal.pmed.1004569

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 02 Aug 2025) [No new digest content identified]

PLoS One

http://www.plosone.org/ [Accessed 02 Aug 2025] [No new digest content identified]

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 02 Aug 2025] [No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

August 19, 2025 vol. 122 no. 33 https://www.pnas.org/toc/pnas/122/33 [New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 5, May 2025 https://academic.oup.com/pnasnexus/issue/4/5

Prehospital & Disaster Medicine

Volume 40 - Issue 3 - June 2025 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 197 August 2025 https://www.sciencedirect.com/journal/preventive-medicine/vol/197/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

August 2025 Volume 292 Issue 2053 https://royalsocietypublishing.org/toc/rspb/current Table of Contents

Special feature: The other 1%: Showcasing science and scientists from the Global South and indigenous communities

The other 1%: Showcasing science and scientists from the Global South and indigenous communities. Guest edited by Sarah Brosnan, Stephanie Meirmans, Maurine Neiman, Guadalupe Peralta and Shalene Singh-Shepherd.

Public Health

Volume 244 July 2025 https://www.sciencedirect.com/journal/public-health/vol/244/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

Public Health Reports

Volume 140 Issue 2-3, March-April/May-June 2025 https://journals.sagepub.com/toc/phrg/140/2-3 [Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 9, August 2025 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 21 Issue 3, July 2025 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 02 Aug 2025] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 8 Aug 2025

Distribution of the COVID-19 vaccine: experience in Ecuador

Special report | Spanish |

Risk Analysis

Volume 45, Issue 5 Pages: 969-1185 May 2025 https://onlinelibrary.wiley.com/toc/15396924/current [Reviewed earlier]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 02 Aug 2025]
[No new digest content identified]

Royal Society Open Science

August 2025 Volume 12 Issue 8 https://royalsocietypublishing.org/toc/rsos/current [New issue; No digest content identified]

Science

https://www.science.org/toc/science/current Volume 389 | Issue 6762 | 21 Aug 2025 Editorial

Rewiring science diplomacy

BY Vaughan C. Turekian, Peter Gluckman 21 Aug 2025

Over the past two decades, science diplomacy has been cast in a glow of hopeful optimism, especially by academics. It was framed as the art of bridge building, opening channels between adversaries, a common language across cultures, and a refuge for dialogue in times of political rupture. This aspirational model helped connect scientists across geopolitical divides, built trust, and was a cornerstone of post—Cold War internationalism. In recent years, these ideals have become increasingly affected by the pull of geopolitics. As multilateralism falters and geopolitical rivalries intensify, nations are putting greater emphasis on science and technology as strategic assets. For science diplomacy to remain relevant in this era, it must develop a new mode of engagement—transactional science diplomacy.

Whereas the aspirational model emphasized curiosity and relationship building, its successor, the pragmatic mode, concentrated on shared problem-solving. Of late, there has been a shift to a transactional model, which takes on a more business-like approach with a focus on dealmaking, and near-term returns for the players within broader national strategy. Science's value now is seen as not just a tool of cooperation but also as a currency of negotiation. Agreements are contingent, driven by near-term benefit, and increasingly aimed at advancing national interests.

Consider the conditionality of technology transfer agreements, where access to critical research infrastructure or intellectual property may depend on regulatory concessions, political alignment, or market access guarantees. Countries may trade genomic data for vaccine doses or offer collaboration on artificial intelligence research only in exchange for policy alignment. Scientific cooperation becomes a calculated exchange—often asymmetrical, narrowly scoped, and susceptible to disruption.

This transformation reflects broader shifts. The US CHIPS and Science Act, the European Union's technological sovereignty agenda, and China's state-led innovation strategy all underscore this trend.

National science systems are being rewired not only to deliver innovation but to protect and project power.

For all the opportunities this change may bring, there are also substantial risks. It might unlock cost sharing on big-ticket research and development, accelerate collaboration in domains determined as national policy priorities (like semiconductors and synthetic biology), and actively attract private-sector engagement. It also encourages results-focused partnerships. However, transactionalism can erode the scientific commons. When science is seen as a bargaining chip rather than a public good, its legitimacy can be undermined. It also risks entrenching power imbalances. High-income countries may dictate terms that exclude or exploit lower-income partners, particularly in the Global South. And it is focused on only the short term, favoring measurable outputs over enduring partnerships and disincentivizing basic science not tied to immediate gains. It risks shifting the emphasis from issues of the global commons to those more narrowly aligned only with national self-interest. A diplomatic challenge is to develop approaches that act on these risks and their interdependence. Yet transactional diplomacy is not inherently malign. It is a logical, even necessary, response to a more fragmented world where national interests resonate with policy-makers and portions of the public whose taxes fund research. The challenge is to integrate it into a strategic framework.

Today, effective science diplomacy requires a new framework—a trimodal model for science diplomacy that is aspirational, pragmatic, and transactional—leveraging the distinct logics and strengths of each approach. Aspirational diplomacy builds empathy and long-term trust. Pragmatic diplomacy reinforces institutions and solves shared problems. Transactional diplomacy delivers immediate, nationally aligned outcomes.

This is not the first time the style of science diplomacy has changed. The aspirational model gave way to pragmatic diplomacy that reinforces institutions committed to science diplomacy and solves shared problems. Over the past year, diplomacy has started yielding to quid pro quo relationships. But these approaches are not mutually exclusive. Indeed, their integration is essential. Technology diplomacy, for instance, may begin with a transactional agreement—access to quantum research labs in exchange for regulatory alignment—but can evolve into pragmatic infrastructure building or more idealistic collaboration over time. Recognizing which approach is appropriate, and how to move between them, should be central to policy design, the defining role of the science diplomat.

With blurring boundaries between science, policy, and diplomacy, fluency across all three domains will be a prerequisite. A new generation of science diplomats must be trained not only in negotiation and dealmaking but in the ethics of exchange, the value of open science, and the mechanics of multilateral engagement.

The growth of transactional science diplomacy need not mean the end of trust-based collaboration or the fragmentation of scientific cooperation. If managed carefully, it can coexist with and even reinforce other forms of diplomacy.

Policy Forum

<u>Disrupting the biospecimen "treasure trove": Practice, precedent, and future directions</u>

BY Leslie E. Wolf, Samantha Kench, Marielle Gross

21 Aug 2025: 784-786

Decentralized biobanking can reconnect individuals to their specimens, democratizing data ownership

Volume 389 | Issue 6761 | 14 Aug 2025

Editorial

Scientists' role in defending democracy

BY Gretchen Goldman, Erica Chenoweth

Volume 389 | Issue 6760 | 7 Aug 2025

Special issue - Evolving immunity

Introduction to Special Issue

The multifunctional immune system

BY Sarah Ross, Caroline Ash 07 Aug 2025: 586-587

Editorial

The Columbia deal is a tragic wake-up call

BY H. Holden Thorp

31 Jul 2025:

Policy Forum

Quantum technology governance: A standards-first approach

BY Mateo Aboy, Urs Gasser, I. Glenn Cohen, Mauritz Kop

07 Aug 2025: 575-578

Standards offer a flexible, globally harmonized path to govern early-stage quantum technologies while preserving innovation, security, and international cooperation

Science and Engineering Ethics

Volume 31, Issue 4 August 2025 https://link.springer.com/journal/11948/volumes-and-issues/31-4 [Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 812| 20 Aug 2025 https://www.science.org/toc/stm/current

Research Articles

Synchronized dynamics of dengue across the Americas

BY Talia M. Quandelacy, et al.

20 Aug 2025

Dengue has strong synchrony across the Americas, indicating that a mix of intrinsic and extrinsic factors drives epidemic transmission dynamics.

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 02 Aug 2025] [No new digest content identified]

Social Science & Medicine

Volume 380 September 2025 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles

[Accessed 02 Aug 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 3 June 2025

https://link.springer.com/journal/11017/volumes-and-issues/46-3

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 66 July-August 2025

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/66/suppl/C

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 7 Pages: i-iv, 577-748 July 2025 https://onlinelibrary.wiley.com/toc/13653156/current

[Reviewed earlier]

Vaccine

Volume 61 13 August 2025

https://www.sciencedirect.com/journal/vaccine/vol/61/suppl/C

Commentary

Discussion

<u>Strategies to improve interprofessional communication regarding maternal and infant RSV immunization</u>

Tamima Hossain, Honora Quinn Burnett, Sarah Schaffer DeRoo

Article 127366

Discussion Abstract only

Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact

Ibrahim Adebayo Hassan, Jeremiah Babatunde Araoye, Dimeji Abdulsobur Olawuyi, Fortune Benjamin Effiong

Article 127376

Discussion Abstract only

It's time to change how we vaccinate for measles

Benjamin L. Sievers, Eric L. Sievers

Article 127382

Short communication Open access

Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 17–21 February 2025

Philipp Lambach, Sheetal Silal, Alyssa N. Sbarra, Mitsuki Koh, ... Xuan-Yi Wang

Article 127384

Review article Open access

<u>Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review</u>

Asia Akther, Cassandra Laurie, Tara Elton-Marshall, Valentina Ly, Giorgia Sulis Article 127331

Review article Open access

<u>COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials</u>

Sima Mohammadi, Malede Mequanent Sisay, Putri Widi Saraswati, Alhadi Khogali Osman, ... Fariba Ahmadizar

Article 127342

Research article Abstract only

<u>Childhood vaccination catch-up and recovery plans for mitigating immunity gap post the COVID-19 pandemic: A case study of selected African countries</u>

Abu Sadat Mohammad Sayem, Godfrey Musuka, Phionah Lynn Atuhebwe, Ibrahim Dadari, Anisur Rahman Siddique

Article 127328

Research article Open access

What are the key features of an equitable global vaccine strategy for the next pandemic? A qualitative study of pandemic control experts

Ayodamope Fawole, Beth Boyer, Minahil Shahid, Ipchita Bharali, ... Gavin Yamey Article 127377

Research article Abstract only

<u>Vaccination against cholera in crisis: Coverage and cost efficiency in Sudan (2023–2024)</u>
Ahmad Izzoddeen, Mohammed Elhussien, Omayma Abdalla, Mawahib S.J. Rashid, ... Dalya Eltayeb
Article 127402

Vaccines

https://www.mdpi.com/journal/vaccines

[Accessed 02 Aug 2025] Open Access Review

Review of Human Papillomavirus Vaccination Programs in United States Schools

by Cassandra Duran, Aditi Gupta, Lynda Aririguzo, Norma Castillo and Sanghamitra M. Misra Vaccines 2025, 13(9), 894; https://doi.org/10.3390/vaccines13090894 (registering DOI) - 23 Aug 2025 Abstract

Background: School vaccination programs (school-based and school-located) that include the human papillomavirus (HPV) vaccine have been implemented throughout the United States since 2009. Methods: We conducted a review of school HPV vaccination programs in PUBMED, Google Scholar, Web of Science, Ovid, Medline, and [...]

Open Access Review

A Review of Insights on Vaccination Against Respiratory Viral Infections in Africa: Challenges, Efforts, Impacts, and Opportunities for the Future

by Paul Gasana, Noel Gahamanyi, Augustin Nzitakera, Frédéric Farnir, Daniel Desmecht and Leon Mutesa

Vaccines 2025, 13(9), 888; https://doi.org/10.3390/vaccines13090888 - 22 Aug 2025

Abstract

Background: Respiratory viral infections such as influenza, COVID-19, and respiratory syncytial virus (RSV) are considered as major public health threats in Africa. Despite global advancements in vaccine development, persistent inequities in access, delivery infrastructure, and public trust limit the continent's capacity to [...]

Open Access Article

<u>Putting the Polio Workforce to Work in a Public Health Crisis: Contributions of the National Stop Transmission of Polio (NSTOP) Program to the COVID-19 Response in Pakistan</u>

by Aslam Pervaiz, Rana Muhammad Safdar, Mumtaz Ali Laghari, Nadeem Shah, Amjad Mehmood, Kifayat Ullah, Richard Franka and Chukwuma Mbaeyi

Vaccines 2025, 13(8), 875; https://doi.org/10.3390/vaccines13080875 - 19 Aug 2025 Abstract

Background: Pakistan reported its first case of COVID-19 in February 2020 and joined other countries in activating a national emergency response following the declaration of the COVID-19 pandemic by the World Health Organization (WHO). Playing a vital role in the early phase [...]

Open Access Review

New Vaccine Introduction in Middle-Income Countries Across the Middle East and North Africa—Progress and Challenges

by Chrissy Bishop, Deeksha Parashar, Diana Kizza, Motuma Abeshu, Miloud Kaddar, Abdallah Bchir, Atef El Maghraby, Hannah Schirrmacher, Zicheng Wang, Ulla Griffiths, Shahira Malm, Sowmya Kadandale and Saadia Farrukh

Vaccines 2025, 13(8), 860; https://doi.org/10.3390/vaccines13080860 - 14 Aug 2025

Abstract

Background/Objectives: The middle-income countries (MICs) in the Middle East and North Africa (MENA) region face multifaceted challenges—including fiscal constraints, conflict, and vaccine hesitancy—that impede the timely introduction of critical vaccines. This study examines the status, barriers, and facilitators to introducing three critical [...

Open Access Viewpoint

<u>Fast-Tracking Vaccine Manufacturing: CEPI's Rapid Response Framework for the 100 Days Mission</u>

by June Kim, Ramin Sabet-Azad, Dimki Patel, Gene Malin, Syed Hassan Askary and Anna Särnefält Vaccines 2025, 13(8), 849; https://doi.org/10.3390/vaccines13080849 - 11 Aug 2025

Abstract

CEPI (the Coalition for Epidemic Preparedness Innovation)'s CMC rapid response framework is developed to support accelerated vaccine development, manufacturing, and roll-out for various outbreak scenarios to achieve the 100 Days Mission. The framework outlines coordinated deliverables across five functional areas: manufacturing processes, formulation, [

Open Access Article

Awareness, Preference, and Acceptance of HPV Vaccine and Related Influencing Factors Among Guardians of Adolescent Girls in China: A Health Belief Model-Based CrossSectional Study

by Shuhan Zheng, Xuan Deng, Li Li, Feng Luo, Hanqing He, Ying Wang, Xiaoping Xu, Shenyu Wang and Yingping Chen

Vaccines 2025, 13(8), 840; https://doi.org/10.3390/vaccines13080840 - 6 Aug 2025 Abstract

Background: Cervical cancer poses a threat to the health of women globally. Adolescent girls are the primary target population for HPV vaccination, and guardians' attitude towards the HPV vaccine plays a significant role in determining the vaccination status among adolescent girls. Objectives:

Value in Health

August 2025 Volume 28 Issue 8 p1141-1304 https://www.valueinhealthjournal.com/current POLICY PERSPECTIVE

<u>Synergizing Needs Assessments and Patient Preference Studies for Enhanced Patient-Centered Decision Making in Healthcare</u>

Elise Schoefs, et al.

Published online: May 15, 2025

p1253-1258

SYSTEMATIC LITERATURE REVIEW

A Systematic Review and Meta-Analysis of Health-State Utility Values for Infectious Diseases With Pandemic Potential and Associated Vaccine Adverse Reactions

Taito Kitano, et al., Lilly Engineer Published online: March 04, 2025

p1280-1287

World Development

Volume 192 August 2025 https://www.sciencedirect.com/journal/world-development/vol/192/suppl/C [Reviewed earlier]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Pre-Print Servers

arxiv

https://arxiv.org/

[Accessed 02 Aug 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2508.15623 [pdf, html, other]

<u>Beyond Traditional Surveillance: Harnessing Expert Knowledge for Public Health Forecasting</u>

Garrik Hoyt, Eleanor Bergren, Gabrielle String, Thomas McAndrew

Gates Open Research

https://gatesopenresearch.org/browse/articles

[Accessed 02 Aug 2025]

[No new digest content identified]

medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 02 Aug 2025]

<u>Vaccine demands to achieve outbreak control for MPXV Clade I with one-time mass campaign in sub-Saharan Africa: scenario-based modelling study</u>

Shihui Jin, Toshiaki R. Asakura, Hiroaki Murayama, David Niyukuri, Diafuka Saila-Ngita, Jue Tao Lim, Akira Endo, Borame Dickens

medRxiv 2025.01.17.25320753; doi: https://doi.org/10.1101/2025.01.17.25320753 Revision

Anticipating HIV Vaccines: A Cross-cultural Behavioral Economic Demand Analysis

Promise Tewogbola, Oluwakamikun Faith Adekunle, Deborah Odaudu, Tolulope Oyewole medRxiv 2025.05.11.25327407; doi: https://doi.org/10.1101/2025.05.11.25327407 Revision

Mpox clinical and epidemiological patterns in the Central African Republic: a systematic review and meta-analysis

Fabrice Zobel Lekeumo Cheuyem, Davy Roméo Takpando-le-grand, Chabeja Achangwa, Lionel Berthold Keubou Boukeng, Solange Dabou, Henri Donald Mutarambirwa, Raissa Katy Noa Otsali, Ariane Nouko, Michel Franck Edzamba, Martine Golda Mekouzou Tsafack, Armel Evouna Mbarga, Georges Nguefack-Tsague

medRxiv 2025.07.09.25331215; doi: https://doi.org/10.1101/2025.07.09.25331215 Revision

<u>Efficacy and side effects of the Herpes Zoster vaccine in immunocompromised individuals – a systematic review</u>

Daniela Marcos Raposo, David Vilhena Catarino Brito, Carla Soraia Mateus Correia, Sónia Marina Teixeira Santos, Ana Isabel Franganito Sardo

medRxiv 2025.08.12.25333482; doi: https://doi.org/10.1101/2025.08.12.25333482

ASSESSMENT OF CHILDHOOD VACCINE IMMUNIZATION COVERAGE, CARD RETENTION, AND COMPLIANCE IN BAYELSA STATE POST-GAVI SUPPORT: A HOUSEHOLD SURVEY OF CHILDREN AGED 0-59 MONTHS

Ebiakpor Bainkpo Agbedi, Mordecai Oweibia, Christopher Peres Ekiyor medRxiv 2025.08.11.25333409; doi: https://doi.org/10.1101/2025.08.11.25333409 Revision

<u>Effect of SMS Reminders on Childhood Vaccination Coverage in Rural Sub-Saharan Africa:</u> <u>A Systematic Review Protocol</u>

Mordecai Oweibia, Gift Cornelius Timighe, Tarimobowei Egberipou, Ebiakpor Bainkpo Agbedi, Ekadi Francis Tamaradielaye

medRxiv 2025.08.08.25333335; doi: https://doi.org/10.1101/2025.08.08.25333335

<u>Factors associated with influenza vaccination among urban community-dwelling Chinese</u> <u>elderly: results from a multicity cross-sectional study</u>

Jiayue Guo, Lili You

medRxiv 2025.08.12.25333514; doi: https://doi.org/10.1101/2025.08.12.25333514

The Impact of National Context on COVID-19 Vaccine Hesitancy Across Europe: A Multi-Level Approach

Michael Bergmann, Arne Bethmann, Tessa-Virginia Hannemann, Alexander Schumacher, Nikolaos Theodoropoulos

medRxiv 2025.08.11.25333435; doi: https://doi.org/10.1101/2025.08.11.25333435

WHO Infection Prevention and Control Health Facility Rapid Assessment Tool for Ebola and Marburg Diseases: a validation mixed-method study

Patrick Mirindi, Maria Clara Padoveze, Steacy Mearns, Victoria Willet, Rony R. Bahatungire, Elizabeth Katwesigye, Michael Mutegeki, Geofrey M. Bukombi, Alex Wasomoka, Patrick Kafeero, Emmanuel Damba, Brian Kasuzi Omongole, Marvin Malikisi, Judith Nanyondo, Rebecca Suubi, Lamorde Mohammed, Kyobe Henry, Diana Atwine, Doreen A. Nabawanuka, Dorothy Kabasinguzi Byaruhanga, Anita Enane, Deborah Barasa, Tendai Makamure, Babacar Ndoye, Jane Ruth Aceng-Ocero, Landry Cihambanya, Charles Olaro, April Baller

medRxiv 2025.08.08.25333289; doi: https://doi.org/10.1101/2025.08.08.25333289

The burden of pertussis disease and vaccination coverage in Australian adults attending primary health care

Aye M. Moa, Juan C. Vargas-Zambrano, Hubert Maruszak, Valentina Costantino, C. Raina MacIntyre medRxiv 2025.08.09.25333139; doi: https://doi.org/10.1101/2025.08.09.25333139

<u>Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Adults in the United States:</u> <u>Clinical and Economic Value</u>

Katherine Hicks, Ziyi Xiao, Kelly Fust, Michele Kohli, Kyle Paret, Weijie Zhang, Maria de Pilar Martin Matos, Keya Joshi, Parinaz Ghaswalla

medRxiv 2025.08.01.25332812; doi: https://doi.org/10.1101/2025.08.01.25332812

<u>Insights on the Implementation Strategies for a Potential New Tuberculosis Vaccine in</u> South Africa

Katherine A. Thomas, Choice Okoro, Thobani Ntshiqa, Verena Damovsky, Deanne Goldberg, Omphile Ramokhoase, Rebecca A Clark, Waasila Jassat, Gavin J Churchyard, Fareed Abdullah, Mmamapudi Kubjane, Janet Seeley, Salome Charalambous, Richard G White

medRxiv 2025.08.01.25332725; doi: https://doi.org/10.1101/2025.08.01.25332725

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
Preprint

<u>The Mpox Contextual Data Specification Package: A Data Curation Toolkit to Support Collaborative Pathogen Genomic Surveillance</u>

Emma Griffiths, Rhiannon Cameron, Charlotte Barclay, Nithu Sara John, Damion Dooley, and 31 more

Date created: 2025-08-22 Date modified: 2025-08-22

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 02 Aug 2025] [No new digest content identified]

* * * *

Think Tanks

Brookings [to 02 Aug 2025] http://www.brookings.edu/ Reports, Events No new digest content identified.

Center for Global Development [to 02 Aug 2025]

https://www.cgd ev.org/ All Research CGD NOTE

Globalizing Vaccines: A Post-COVID Perspective on Industrial Policy, International Health Cooperation, and the Characteristics of Vaccine Production

William D. Savedoff

August 13, 2025

The global response to COVID-19 saw rapid vaccine development and ambitious efforts like COVAX to ensure equitable access, but national self-interest ultimately prevailed, leaving many countries without timely supplies and sparking calls to diversify vaccine manufacturing. While numerous fragmented ...

Chatham House [to 02 Aug 2025]

https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

Council on Foreign Relations [to 02 Aug 2025]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [to 02 Aug 2025] https://www.csis.org/ Reports [Selected]

<u>Opportunities to Strengthen U.S. Biosecurity from AI-Enabled Bioterrorism: What Policymakers Should Know</u>

Georgia Adamson and Gregory C. Allen break down emerging AI-enabled bioterrorism risks and how policymakers can strengthen U.S. biosecurity for the AI age.

Report by Georgia Adamson and Gregory C. Allen — August 6, 2025

Kaiser Family Foundation/KFF [to 02 Aug 2025]

https://www.kff.org/search/?post_type=press-release
Newsroom

The Problem Isn't Trust in Vaccines, It's That People Don't Know Who to Trust

Aug 19, 2025

In a new "Beyond the Data" column, KFF's President and CEO Dr. Drew Altman analyzes years of KFF polling on vaccines in light of the current controversies about them. The real problem, he says, is not lack of public confidence in the safety of vaccines — few say they are unsafe — it's that polarization

and misinformation have eroded confidence in what's true or not, and in scientific institutions people used to rely on for the facts.

Overview of President Trump's Executive Actions on Global Health

Aug 15, 2025

This guide *Fact Sheet*

provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts. This resource identifies each executive action, describes its purpose and actions taken, and outlines the implications and what happens next for each. The resource will be updated as needed.

Kindergarten Routine Vaccination Rates Continue to Decline

Aug 5, 2025

Issue Brief

This issue brief provides an update on the latest trends in kindergarten children's routine vaccination and exemption rates. Over three-quarters (39) of states had measles, mumps, rubella (MMR)vaccination rates below the "target" rate of 95% for the 2024-2025 school year.

McKinsey Global Institute [to 02 Aug 2025]

https://www.mckinsey.com/mgi/overview

No new digest content identified.

ODI [Overseas Development Institute] [to 02 Aug 2025]

https://odi.org/en/publications/

Publications [Selected]

<u>Vulnerability of low- and middle-income countries to the impacts of aid cuts and US tariff increases</u>

14 August 2025 Emerging analysis

Recent cuts to official development assistance (ODA) from the US and EU, coupled with new and higher US tariffs, pose a significant threat to the global economy, putting low- and middle-income countries (L&MICs) at heightened risk of economic instability.

Pew Research Center [to 02 Aug 2025]

https://www.pewresearch.org/ Latest Publications [Selected]

Report Aug 21, 2025

U.S. Unauthorized Immigrant Population Reached a Record 14 Million in 2023

The number of unauthorized immigrants in the U.S. reached an all-time high after two consecutive years of record growth.


Report Aug 19, 2025

International Opinion on Global Threats

Adults across 25 countries see the spread of false information online, the condition of the global economy and terrorism as major threats today.

Around 7 in 10 adults across nations surveyed view false information online, global economic conditions and terrorism as major threats

Median % who say each of the following is (a) ____ to their country



Note: Percentages are medians based on 25 countries. Source: Spring 2025 Global Attitudes Survey. "International Opinion on Global Threats"

PEW RESEARCH CENTER

Rand [to 02 Aug 2025]

https://www.rand.org/pubs.html Published Research [Selected] Expert Insights Aug 18, 2025

Exploring the Offense-Defense Balance of Biology: Identifying and Describing High-Level Asymmetries

Advancements in and democratization of synthetic biology capability risk introducing destabilizing asymmetries between offensive and defensive uses of biotechnology.

Research Aug 15, 2025

<u>Evaluating the Cultural Adaptation of Evidence-Based HIV Prevention Interventions for African Immigrant Women: Exploratory Pilot Mixed-Methods Study</u>

Culturally-adapted HIV prevention programs for African-born Black women in the US showed high feasibility and acceptability, addressing key gaps and supporting future trials to boost condom and PrEP use.

Expert Insights Aug 13, 2025

Assessing the Value of a CERN-Like Multinational Research Organization for AI

In this paper, the authors use the strategic assessment framework known as Porter's five forces model to assess potential investments in an artificial intelligence research organization based on the European Organization for Nuclear Research (CERN).

Research Aug 4, 2025

Strengthening Compliance and Verification Under the Biological Weapons Convention

This paper outlines a practical, science-informed framework for compliance and verification under the BWC. It proposes tools and indicators to support risk assessment, detection and deterrence of biological weapons, and introduces a sliding scale to evaluate levels of compliance based on national capacities.

Urban Institute [to 02 Aug 2025] https://www.urban.org/publications **New Research Publications - Selected**

Brief

<u>Public Perceptions of 'Food Is Medicine' Programs and Implications for Policy</u> August 20, 2025

In this brief, we assess public perceptions of "Food Is Medicine" (FIM) programs, such as medically tailored meals, medically tailored groceries, and produce prescriptions. These programs aim to improve health by providing individuals with nutritious food through collaborations between the health care system and community partners...

World Economic Forum [to 02 Aug 2025]

https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

Draft guideline on the quality aspects of mRNA vaccines

EMA Draft: consultation open Consultation dates: 31/03/2025 to 30/09/2025

Reference Number: EMA/CHMP/BWP/82416/2025

Summary:

This guideline addresses the quality aspects of mRNA vaccines. It addresses specific aspects regarding the manufacturing process, characterisation, specifications and analytical control of mRNA vaccines, as well as the definition of starting materials, active substance and finished product for mRNA vaccines. Additional regulatory considerations are provided for changes in existing mRNA vaccine strains, bivalent and multivalent vaccines, self-amplifying mRNA vaccines, other delivery systems and use of platform technology/prior knowledge. The scope of this guideline is applicable to mRNA vaccines against infectious diseases. Other mRNA-based medicinal products are out of scope of this guideline, although relevant parts of this guideline may be applicable to those. It is not intended to address specific requirements for mRNA vaccines to be used in clinical trials, however the scientific principles described may also be applicable during pharmaceutical development.

Agency Information Collection Activities; Proposed Collection; Comment Request; Emergency Use Authorization of Medical Products

A Notice by the Food and Drug Administration on 07/14/2025 **Comment period ends 09/12/2025.**

OMB Control Number 0910-0595—Extension SUPPLEMENTARY INFORMATION:

This information collection helps support implementation of Agency policies applicable to the authorization for medical products for use in emergencies under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360bbb-3, 360bbb-3a, and 360bbb-3b). For more information regarding emergency use authorization (EUA), visit our website at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.

The FD&C Act permits the Commissioner of Food and Drugs (the Commissioner) to authorize the use of unapproved medical products for humans and animals, or unapproved uses of approved medical products for humans and animals, during an emergency declared under section 564 of the FD&C Act. The data to support issuance of an EUA must demonstrate that, based on the totality of the scientific evidence available to the Commissioner, including data from adequate and well-controlled clinical trials (if available), it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing a serious or life-threatening disease or condition (21 U.S.C. 360bbb-3(c)).

Also, under section 564 of the FD&C Act, the Commissioner may establish conditions on issuing an authorization that may be necessary or appropriate to protect the public health...

<u>ICH - E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials; International Council for Harmonisation; Draft Guidance for Industry; Availability</u>

A Notice by the Food and Drug Administration on 07/21/2025 **Comment period ends 09/19/2025** *SUMMARY:*

...The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance is intended to provide general principles on the conduct of clinical trials that include pregnant and breastfeeding women to inform evidence-based decisions on safe and effective use of medicinal products by these populations.

The draft guidance includes approaches to generating data that support informed decision-making on the safety, dosing, and efficacy of medicinal products during pregnancy and breastfeeding. Additionally, the draft guidance includes recommendations for recruiting and retaining pregnant and breastfeeding women in clinical trials, while reducing burden and harm on these participants. *Background*

...The recommendations found in this draft guidance are the product of the Efficacy Working Group of the ICH. Comments about this draft will be considered by FDA and the Efficacy Expert Working Group.

The draft guidance outlines strategies and considerations for developing and implementing clinical studies that include pregnant or breastfeeding women. This draft guidance includes approaches to plan, collect data, evaluate outcomes, and monitor safety of pregnant and breastfeeding women participating in clinical trials safely and ethically. Additionally, the draft guidance includes recommendations for recruiting and retaining pregnant and breastfeeding women in clinical trials. The draft guidance also emphasizes reduction of burden on pregnant and breastfeeding women participating in these trials.

This draft guidance has been left in the original ICH format. The final guidance will be reformatted and edited to conform with FDA's good guidance practices regulation (21 CFR 10.115) and style before publication.

Solicitation of Nominations for Appointment to the Advisory Council for the Elimination of Tuberculosis A Notice by the Centers for Disease Control and Prevention on 07/11/2025. **Nominations must be received no later than September 30, 2025**SUMMARY:

In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Advisory Council for the Elimination of Tuberculosis (ACET). ACET consists of 10 experts including the Chair in fields associated with public health, epidemiology, immunology, infectious disease, pulmonary disease, pediatrics, tuberculosis, microbiology, and preventive health care delivery. SUPPLEMENTARY INFORMATION:

The Advisory Council for the Elimination of Tuberculosis (ACET) provides advice and recommendations regarding the elimination of tuberculosis (TB) to the Secretary, Department of Health and Human Services (HHS); the Assistant Secretary for Health, HHS; and the Director, Centers for Disease Control and Prevention (CDC). ACET (a) makes recommendations on policies, strategies, objectives, and priorities; (b) addresses development and application of new technologies; (c) provides guidance and review of CDC's TB prevention research portfolio and program priorities; and (d) reviews the extent to which progress has been made toward eliminating TB.

* * * *

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u> and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.